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ABSTRACT OF DISSERTATION

The Relationship Between High Sensitivity C-Reactive Protein,
Metabolic Syndrome and Exercise.
by
Micheline A. Vargas
Doctor of Public Health Candidate in Preventive Care
Loma Linda University, Loma Linda University, 2005
Lee S. Berk, DrPH and Edward K. Fujimoto, DrPH, Co-Chairmen

Background: It is well known that regular physical activity is associated with
lower risk of chronic diseases such as diabetes and cardiovascular disease. Physical
activity is also considered an important determinant of metabolic syndrome. All levels of
metabolic syndrome, diabetes, and cardiovascular disease are thought tO involve
inflammation. Physical activity may reduce risk, at least in part, by modifying the
inflammatory process. Recent studies have demonstrated an inverse relationship between
inflammatory markers, such as high sensitivity C-reactive protein (hs-CRP), and physical
activity. Elevated hs-CRP appears to be an independent predictor of both CVD and
diabetes. Recent evidence also suggests that hs-CRP is positively associated with all
metabolic syndrome characteristics: low high density lipoprotein (HDL),
hypertriglyeridemia, hypertension, obesity, and abnormal glucose.
Purpose: The purpose of this study was to examine the relationship between hsCRP, metabolic syndrome and physical activity. Understanding this relationship will
111

provide insight into the potential of physical activity as a therapeutic option to reduce
cardiovascular disease risk.
Methodology: This study relied on a cross-sectional, retrospective analysis of an
archival database from the Center for Health Promotion (CHP). Study participants were
obtained from a pool of 1,072 men and women patients at the Center of Health Promotion
(CHP) at Loma Linda University. Of the 1,072 pool, 173 individuals met the inclusion
criteria and were the subjects of the study. Any missing data variables were imputed
using the maximum likelihood method (EM) in SYSTAT version 10; SPSS02000. The
distribution of hs-CRP, the dependent variable of greatest interest, was positively skewed.
Therefore, a log transformation was applied to hs-CRP values for all analyses. Simple
regression/correlation analysis was used to evaluate the relationships between log (CRP)
and each of the relevant variables: VO2max (ml•kg-1•min-1), metabolic syndrome, and the
physical activity status. The following relationships were explored: (1) hs-CRP and
metabolic syndrome characteristics, (2) hs-CRP and VO2max, (3) VO2max and metabolic
syndrome characteristics, and (4) VO2max and physical activity status. Pearson Chisquare analysis was used to determine if a threshold level of physical activity was
associated with hs-CRP changes.
Results: Hs-CRP increased linearly with the number of metabolic syndrome
characteristics (p = 0.00022). Inverse associations were found between hs-CRP and
VO2max (p = 0.00008) and between VO2max and the number of metabolic syndrome
criteria (p = 0.00004). VO2max was positively associated with PA (p = 0.00000).
Subjects engaging in 2-3 hours of PA per week had hs-CRP levels < 2.5 mg/L (p =
0.01817).
iv

Conclusions: Physical activity may reduce risk by modifying the inflammatory
process. We found that hs-CRP and metabolic syndrome severity were reduced in those
with a higher cardiorespiratory fitness level. These associations are suggested
mechanisms by which cardiorespiratory fitness reduces the risk of CVD and diabetes.
Our findings support physical activity recommendations set forth by both the Surgeon
General and the American College of Sports Medicine. This study was also in support of
recommendations set forth by the ATP-III report to use physical activity as first-line
therapy for the management of metabolic syndrome.
Significance to Preventive Care: Preventive Care Specialists often prescribe
physical activity as a way of reducing chronic diseases such as cardiovascular disease and
diabetes. Reducing hs-CRP via regular exercise may be an intervention by which
exercise reduces risk of chronic disease. This study strengths the argument that regular
physical activity reduces inflammation and metabolic syndrome risk factors thereby
providing protection against the number one killer in the U.S., cardiovascular disease.
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CHAPTER 1
INTRODUCTION
A. Statement of the Problem
It is well known that inflammation is involved in mediating all stages of the
atherosclerotic disease process (Pearson et al., 2003; Libby, Ridker, & Maseri, 2002).
Hence, markers of inflammation have been examined as potential tools in the prediction
of cardiovascular events. Of these markers, the acute-phase reactant, high sensitivity Creactive protein (hs-CRP), has generated significant interest (Szmitko et al., 2003).
Emerging evidence suggests that hs-CRP is one of the strongest independent predictors of
cardiovascular events (Szmitko et al., 2003; Yeh & Willerson, 2003). According to
LaMonte et al. (2002), elevated hs-CRP is associated with a 2 to 5-fold increase in
cardiovascular event risk.
Although hs-CRP has been considered only a biomarker, recent evidence suggests
that it may directly promote atherosclerosis. According to Szmitko et al. (2003), hs-CRP
provokes inflammation and endothelial dysfunction. It appears to reduce transcription of
endothelial nitric oxide synthase (eNOS), which leads to a diminished release of nitric
oxide (NO). This is turn reduces protection against vascular injury and inflammation.
Hs-CRP causes further disruption to endothelial homeostasis by stimulating the release of
endothelin-1 (ET-1) and interleukin (IL)-6, by upregulating adhesion molecules
(intracellular adhesion molecule-1, vascular cell adhesion molecule-1, selectins), and by
stimulating the chemokine monocyte chemoattractant protein-1 (MCP-1). Hs-CRP also
promotes foam cell formation by facilitating LDL uptake by macrophages (Szmitko et al.,
2003; Yeh & Willerson, 2003). Preliminary observations from Szmitko et al. (2003) also
1

indicate that hs-CRP up-regulates nuclear factor KappaB (NF- KB), which facilitates
transcription of several proatherosclerotic genes. Hs-CRPs proatherogenic effects extend
beyond the endothelium to the vascular smooth muscle (VSM). In concentrations known
to predict cardiovascular events, hs-CRP demonstrates up-regulation of angiotensin-type
1 receptors (ATi-R) in vascular SMCs. This augments VSM proliferation, migration,
reactive oxygen species (ROS) production, and restenosis (Szmitko et al., 2003).
Observational studies have provided evidence that physical inactivity and low
cardiorespiratory fitness predict atherosclerotic cardiovascular disease (Blair et al., 1996;
Ekelund et al., 1988; Lakka et al., 1994, Laukkanen et al., 2001; Lee, Blair, & Jackson,
1999; Sandvik et al., 1993), while regular physical activity is associated with lower risk
of coronary heart disease, stroke, and cardiovascular mortality (Erikssen et al. 1998).
Physical activity may reduce risk, at least in part, by modifying the inflammatory process
and reducing endothelial dysfunction. Recent studies have demonstrated an inverse
relationship between inflammatory markers, such as hs-CRP, and physical activity
(Geffken et al., 2001; Rawsen et al., 2003). Higher levels of hs-CRP have also been
associated with obesity and insulin resistance, while physical activity has been associated
with lesser degrees of obesity and insulin resistance. Based on these findings many
researchers have speculated that physical activity may be associated with lower levels of
inflammation via its inverse relationship with obesity and insulin resistance (LaMonte et
al., 2002). Other researchers believe that physical activity reduces hs-CRP independently
(Rawson et al., 2003).
Relatively few studies have examined the effects of physical activity on
inflammatory markers and results are conflicting (Geffken et al., 2001; Smith et al., 1999;
2

Rawsen et al., 2003). This may be due in part to research design. Several of the studies
had an inadequate number of participants and others failed to adjust for body composition
and other confounding variables. According to Pearson et al. (2003) many variables are
associated with hs-CRP levels. Elevated body fat mass, weight loss, elevated blood
pressure, cigarette smoking, metabolic syndrome, diabetes, low HDL cholesterol, high
triglycerides, gender, age, and increased physical activity all appear to influence hs-CRP.
More research is needed to assess the relationship between hs-CRP, metabolic
syndrome and physical activity. Questions remain regarding: (1) the relationship
between cardiorespiratory fitness level and hs-CRP, (2) the threshold level of physical
activity that is associated with changes in hs-CRP, (3) the type of physical activity
needed to reduce hs-CRP, (3) the association between hs-CRP, metabolic syndrome and
cardiorespiratory fitness level, and (4) whether the associations seen between physical
activity and lowered inflammatory markers is mediated by reduced body fat.
B. Purpose of the Study
The purpose of this study was to examine the relationship between hs-CRP,
metabolic syndrome and physical activity. Understanding this relationship will provide
insight into the potential of physical activity as a therapeutic option to reduce
cardiovascular disease risk. This study relied on a cross-sectional, retrospective analysis
of an archival database from the Center for Health Promotion (CHP). Study participants
were obtained from a pool of 1,072 men and women patients at the Center of Health
Promotion (CHP) at Loma Linda University. Of the 1,072 pool, 173 individuals met the
inclusion criteria and were the subjects of the study. Any missing data variables were
imputed using the maximum likelihood method (EM) in SYSTAT version 10;
3

SPSS©2000. Because the percent body fat variable required over 100 imputations to fill
in all of the missing data it was not used in any analyses. The distribution of hs-CRP, the
dependent variable of greatest interest, was positively skewed. Therefore, a log
transformation was applied to hs-CRP values for all analyses. Simple
regression/correlation analysis was used to evaluate the relationships between log(CRP)
and each of the relevant variables: VO2max (ml•kg-1•min-1), metabolic syndrome, and the
physical activity status. The following relationships were explored: (1) hs-CRP and
metabolic syndrome characteristics, (2) hs-CRP and VO2max, (3) VO2max and metabolic
syndrome characteristics, and (4) VO2max and physical activity status. Pearson Chisquare analysis was used to determine if a threshold level of physical activity was
associated with hs-CRP changes. Understanding these relationships provides insight into
the potential of physical activity as a therapeutic option to reduce cardiovascular disease
risk (Church et al., 2002).
C. Research Questions
1. What is the relationship between fitness level and hs-CRP?
2. What is the relationship between hs-CRP, the metabolic syndrome and
cardiorespiratory fitness?
3. Is there a threshold level of physical activity that is associated with changes in hsCRP?
D. Mechanisms
Several theories exist as to how regular physical activity reduces hs-CRP and the
inflammatory process. Mattusch et al. (2000) suggested that hs-CRP levels were
reduced, at least in part, due to enhanced antioxidative defense mechanisms seen after
regular exercise training. It has been reported that well trained athletes have increased
4

activity in muscular and erythrocytic antioxidative enzymes. Animal studies have also
shown improved antioxidant defense mechanisms after exercise training. It may be that
enhanced antioxidative protection reduces the production of IL-6 and other cytokines in
the exercising muscle.
Church et al. (2002) also proposed interleukins as a potential pathway. Evidence
suggests that tumor necrosis factor-a (TNF-a) and IL-6 are involved in hs-CRP
production. TNF-a stimulates the production of IL-6 and IL-6 stimulates the production
of hs-CRP. Regular exercise training appears to lower basal plasma interleukin
concentrations and TNF-a. The release of TNF-a and IL-6 is augmented by the
downregulation of sympathetic stimulation via regular physical activity. Reductions in
TNF- a and IL-6 have been found independently of weight loss, hence, TNF-a and IL-6
may be responsible for reduced hs-CRP in fit individuals (Church et al., 2002).
Smith et al. (1999) found that exercise reduced TNF- a. These researchers
examined the possibility that long-term exercise could favorably alter the production of
cytokines with atherogenic and atheroprotective properties. Cytokines with atherogenic
properties include IL-1, TNF-a, and interferon-y (IFN-y). Cytokines with
atheroprotective properties include IL-4, IL-10, and transforming growth factor beta
(TGF-B). Smith et al. (1999) measured the effects of exercise on the production of these
cytokines along with serum levels of hs-CRP. Following six months of moderate
intensity training proatherosclerotic cytokine production was attenuated, while
atheroprotective cytokine production was increased. These changes were proportionate
to the time participants spent performing repetitive lower-body exercises, suggesting a
dose-response relationship. A reduction in hs-CRP accompanied the changes in immune
5

cell function. This could indicate a systemic decrease in the production of both IL-1 and
TNF-a. These alterations were seen independently of aspirin or other medication use,
dieting, weight loss, and smoking cessation. In addition to reductions in IL-6 and TNF-a,
Smith et al. (1999) found a significant attenuating effect on IFN-y. IFN-y and TNF-a
have been identified in early and advanced atherosclerotic lesions. They appear to
activate endothelial cells, monocytes, macrophages, and smooth muscle cells, hence they
contribute to leukocyte recruitment, endothelial cell procoagulant activity, LDL
oxidation, and foam cell formation. Therefore, reducing these and other
proatherosclerotic cytokines via regular exercise is of value for those persons at risk of
developing cardiovascular disease (Smith et al., 1999).
Several theories exist as to how exercise reduces hs-CRP. These potential
mechanisms along with a reduction in traditional risk factors, such as hypertension,
elevated cholesterol, elevated triglycerides, impaired glucose tolerance, and diabetes
mellitus likely lead to a reduction in hs-CRP and cardiovascular disease. Figure 1 shows
the potential mechanisms by which exercise reduced hs-CRP and cardiovascular disease.
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Figure 1. Potential mechanisms by which exercise reduces hs-CRP and
Cardiovascular Disease (CVD). IL-6 = interleukin-6, TNF-a = tumor necrosis factor-a,
CRP = c-reactive protein, HTN = hypertension, CH = cholesterol, TG = triglyceride, IGT
= impaired glucose tolerance, DM = diabetes mellitus, NO = nitric oxide, ET-1 =
endothilin-1, ICAM = intracellular adhesion molecule, VCAM = vascular cell adhesion
molecule, ATI R = angiotensin type-1 receptor, MCP-1 = monocyte chemoattractant
protein-1, NFKI3 = nuclear factor KB.
E. Significance to Preventive Care
Preventive Care Specialists often prescribe physical activity as a way of reducing
chronic diseases such as cardiovascular disease and diabetes. Physical activity provides
protection to the cardiovascular system via multiple mechanisms: (1) increased
dimension of coronary arteries; (2) improved coagulation system; (3) increased stroke
volume, and (4) increased maximal oxygen uptake (Geffken et al. 2000). Reducing
inflammation (i.e. hs-CRP) via regular exercise may be yet another mechanism by which
exercise decreases risk of chronic disease. This study investigates the impact of regular
physical activity on the inflammatory process and cardiovascular disease risk to confirm
and extend available data. Hence, it will strengthen the argument for regular physical
7

activity and support the Surgeon General's recommendation to include a moderate
amount of physical activity on most, if not all days of the week. This study will also
likely support the theory that regular physical activity, regardless of body fat mass,
reduces risk of chronic disease. This could send yet another public health message. Even
low to moderate amounts of regular physical activity provide protection from the number
one killer in the U.S., cardiovascular disease.

8

CHAPTER 2
REVIEW OF LITERATURE

A. Overview
Atherosclerosis was formerly considered a mere lipid storage disease when in
actuality it involves an ongoing inflammatory response with the endothelium being the
primary site of dysfunction. Advances in basic and experimental science have
established that inflammation is involved in mediating all stages of this disease from
initiation through progression and, ultimately, to atherosclerotic plaque complications
(Pearson et al., 2003; Libby, Ridker, & Maseri, 2002). Several markers of the
inflammatory cascade have been examined as potential tools in the prediction of
cardiovascular events. Among them are markers of systemic inflammation produced in
the liver, such as high sensitivity C-reactive protein (hs-CRP) and serum amyloid A
(SAA); cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a); and
adhesion molecules such as vascular cell adhesion molecule 1(VCAM-1) and
intercellular adhesion molecule-1 (ICAM-1). Of these markers, the acute-phase reactant,
hs-CRP, has generated significant interest (Szmitko et al., 2003). Emerging evidence
suggests that hs-CRP is one of the strongest independent predictors of cardiovascular
events (Szmitko et al., 2003; Yeh & Willerson, 2003). Ridker, Hennekens, Burning, and
Rifai (2000) found that hs-CRP was better than low-density lipoprotein (LDL)
cholesterol at predicting cardiovascular events and according to LaMonte et al. (2002)
elevated hs-CRP is associated with a 2 to 5-fold increase in cardiovascular event risk.
Although, once thought to act only as a biomarker new evidence is showing that hs-CRP
9

plays a more functional role in the atherosclerotic disease process. This new information
is profound and will likely change the way we screen and manage patients (Yeh &
Willerson, 2003).
It is well known that regular physical activity reduces the risk of cardiovascular
disease and recent studies have found an association between physical activity and hsCRP. Greater understanding of this relationship may provide insight into the potential of
exercise as a therapeutic option to reduce hs-CRP (Church et al., 2002). At this time
there are no firm conclusions as to how exercise reduces the inflammatory process or hsCRP. Only a handful of studies have examined the effects of exercise on inflammatory
markers and of those many have presented conflicting results. This may be due in part to
research design. Many lack either a reliable measure of regular physical activity,
adjustments for body weight and other confounding variables, or an adequate number of
participants. The cohorts used also differ significantly making it difficult to compare
results.
This chapter will review epidemiological and experimental evidence regarding the
role of hs-CRP in primary prevention, inflammation in atherosclerosis, the functional role
of hs-CRP in the atherosclerosis process, and the effects of exercise on hs-CRP. Studies
for this review were identified using computer searches of Medline, PubMed, and
prominent peer reviewed journals.
B. Hs-CRP Use in Primary Prevention
Emerging evidence suggests that hs-CRP is one of the strongest independent
predictors of cardiovascular events. It appears to be an even stronger predictor than LDL
cholesterol (Yeh & Willerson, 2003) and it adds prognostic value to the Framingham risk
10

assessment score and all levels of the metabolic syndrome (Szmitko et al., 2003; Ridker,
2003). In the Framingham Heart Study, coronary heart disease occurred in
approximately one third of the individuals with total cholesterol less than 200 mg/dL
(Castelli, 1996).
According to Ridker (2003), over a dozen prospective epidemiological studies
have found a single, non-fasting measure of hs-CRP to be a strong predictor of
cardiovascular events in individuals with no prior history of cardiovascular disease.
Initial data from the Multiple Risk Factor Interventional Trial (MRFIT) (Kuller, Tracey,
Shaten, Meilahn, 1996), the Women's Health Study (Ridker, Hennekens, Buring, and
Rifai, 2000), the Rural Health Promotion Project (Tracy, Lemaitre, Psaty, Ives, Evans,
Cushman, Meilahn, and Kuller, 1997), the NIH-funded Coronary Heart Study (Tracy et
al., 1997), the Physicians' Health Study (Ridker, Cushman, Stampfer, Tracy, and
Hennekens, 1997; Ridker, Cushman, Stampfer, Tracy, and Hennekens, 1998a), the
MONICA-Augsburg Cohort Study (Koenig, Sund, Frohlich, Fischer, Lowel, Doring,
Hutchinson, Pepys, 1999), and the Helsinki Heart Study (Roivainen, Viik-Kajander,
Fischer, Lowel, Doring, Hutchinson, et al., 2000) are just a few of the prospective studies
conducted in the United States and Europe that have found an association between
baseline hs-CRP levels and risk of first cardiovascular event. Hs-CRP's strong predictive
value may be partially explained by its long-term stability during storage. One study
recently found that hs-CRP was a strong predictor of risk even 20 years after the initial
blood samples were acquired (Ridker, 2003). Hs-CRP has a long half-life, it lacks
diurnal variation, and it lacks age and sex dependence (Yeh & Willerson, 2003).
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Simple clinical cut points have been established from event-free survival data
allowing clinicians to interpret hs-CRP levels. An hs-CRP assay, such as Dade Behring,
is needed to detect levels within the normal range (low grade levels). Hs-CRP predicts
cardiovascular events within this normal range (Rifai, Tracy, and Ridker, 1999).
Standard CRP tests determine levels that are increased several hundred-fold if not a
thousand-fold during acute infection and tissue injury and are not able to detect low grade
levels of CRP. Using the hs-CRP assays we can categorize patients as low (<1 mg/L),
moderate (1-3 mg/L), or high risk (3-10 mg/L) for future cardiovascular events. Levels
exceeding 10 mg/L may indicate a possible acute phase response. In this case, the test
should be repeated within a few weeks (Ridker, 2003; Yeh & Willerson, 2003).
In addition to hs-CRP, other biomarkers have been shown to predict myocardial
infarction and stroke. Sophisticated methods have been utilized to measure adhesion
molecules, cytokine activity, and immunologic functions (i.e. ICAM-1, IL-6).
Unfortunately, measures of these biomarkers are often inappropriate for clinical use: the
assays used are often inappropriate for routine clinical use, the protein being measured
has a short half-life, or the marker has not been standardized (Ridker, 2003). Hs-CRP on
the other hand, has a standardized assay and is stable. It has a half life of about 18-20
hours, partly due to its pentraxin structure. This allows the measure to be made from
either fresh or frozen plasma.
The Women's Health Study compared ten biomarkers for vascular disease
(Ridker et al, 2000). The researchers compared lipoprotein(a), homocysteine, IL-6,
soluble ICAM-1, serum amyloid A (SAA), total cholesterol (TC), LDL, Apolipoprotein
B, TC to high density lipoprotein cholesterol (HDL) ratio, hs-CRP, hs-CRP plus TC:HDL
12

ratio. Interestingly, they found that SAA and soluble ICAM-1 were better risk markers
than TC or LDL. The best lipid marker was the TC:HDL ratio, which is consistent with
many epidemiological studies. Hs-CRP was, however, the best predictor of risk. Hs-CRP
screening, on its own, was associated with a 4.4-fold increase in vascular risk in the
study's participants. But, the best overall risk estimate was found when hs-CRP was
combined with TC:HDL ratio (Ridker et al., 2000). In an analysis from the Physicians'
Health Study, Ridker, Glynn, and Hennekens, (1998b) found an interaction between hsCRP and TC:HDL ratio. Hence, using both these parameters may do a better job of
predicting risk than using either alone.
The Women's Health Study prospectively examined the predictive value of LDL
and hs-CRP in 27,939 postmenopausal women for approximately eight years. The
researchers found that hs-CRP was a better predictor of cardiovascular event risk than
LDL (Ridker et al. 2002). Even after adjusting for all Framingham risk score
components, hs-CRP appeared to be an independent risk factor for stroke, myocardial
infarction, and cardiovascular mortality. Women with low LDL levels (<123.7 mg/dL),
but high hs-CRP values were at higher risk for cardiovascular events than the women
with higher LDL (>123.7) levels, but low hs-CRP values (Ridker et al., 2000). Hence,
the addition of hs-CRP to traditional cholesterol testing may improve risk prediction, but
might also improve compliance with preventive approaches. According to Ridker
(2003), it is well established that absolute risk perceived by an individual is directly
related to compliance with lifestyle recommendations. Hs-CRP evaluation may be useful
for this reason alone.
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In addition to its ability to add predictive value to traditional lipid screening, hsCRP also adds prognostic value to all levels of the metabolic syndrome (Szmitko et al.,
2003; Ridker, 2003). Inflammation, not elevated LDL, plays a major role in almost all
processes associated with the metabolic syndrome. Ridker (2003) stated that hs-CRP
levels are associated with triglycerides, obesity, blood pressure, and fasting glucose, all of
which are components of the Adult Treatment Panel III (ATP III) metabolic syndrome
definition. Ridker (2003) examined the possible interrelationships between the metabolic
syndrome, hs-CRP, and cardiovascular events in participants in the Women's Health
Study (n = 14,719). The women were aged 45 and older and apparently healthy with no
prior history of cardiovascular disease or cancer and did not have diabetes at baseline.
The participants had also 'complete data for all components of the metabolic syndrome.
Ridker (2003) found a significant (p-trend <0.0001) linear relationship between the
number of metabolic syndrome criteria and hs-CRP level (0.68 mg/L for women who met
no criteria of the metabolic syndrome to 5.75 mg/L for women who met all 5 criteria).
Festa, D'Agostino, Howard, Mykkanen, Tracy, and Haffner (2000) also found an
association between the metabolic syndrome and hs-CRP. In the Insulin Resistance
Atherosclerosis Study (IRAS), Festa et al. (2000) found that hs-CRP levels in nondiabetic subjects increased in a monotonic fashion as the number of metabolic disorders
increases. According to Ridker (2003), insulin sensitivity and impaired fibrinolysis,
which are additional factors associated with the metabolic syndrome also appear to be
associated with hs-CRP. Ridker (2003) also stated that several prospective studies have
found hs-CRP to predict type 2 diabetes. Risk for developing type 2 diabetes appears to
increase 4 to 6-fold in individuals with hs-CRP levels >3mg/L. These studies further
14

suggest inflammation, atherosclerosis, and diabetes as interconnected disorders of the
innate immune system.
Studies conducted in both the U.S. and Europe have consistently found a
relationship between an individual's baseline hs-CRP level and future vascular risk. In
most cases this has been seen independent of cholesterol levels, blood pressure, age,
smoking, and diabetes. Effects are seen in men and women, middle age and elderly,
those with low absolute risk and those with high absolute risk for vascular events
(Ridker, 2003). Although, hs-CRP appears to be associated with an increased risk for
cardiovascular disease controversy surrounds the role hs-CRP actually plays in the
atherosclerotic disease process. In order to further understand hs-CRPs role as an
inflammatory biomarker or a possible risk factor, we must first understand the link
between inflammation, endothelial dysfunction, and atherosclerosis.
C. Endothelial Dysfunction, Inflammation, and Atherosclerosis
The role of inflammation has become a well established theory in describing the
atherosclerotic disease process (Pearson et al., 2003; Libby, Ridker, and Maseri et al.,
2002). From a pathological standpoint all stages from initiation to plaque rupture are
considered to be an inflammatory response to injury. The traditional triggers that
promote atherogenesis include, cigarette smoking, atherogenic lipoproteins, hypertension,
and hyperglycemia. These triggers encourage a number of noxious stimuli that elicit
secretion of both leukocyte soluble adhesion molecules, which facilitate monocyte
attachment to the endothelium, and chemotactic factors, which enable the monocytes to
migrate into the subendothelial space (Pearson et al., 2003; Libby, Ridker, and Maseri et
al., 2002).
15

Endothelial injury results in "dysfunction". According to Szmitko et al. (2003)
dysfunction involves an imbalance in endothelium-derived relaxing factors, such as nitric
oxide (NO) and contracting factors, such as endothelin-1 (ET-1), angiotensin, and
oxidants. The imbalance between endothelial-derived vasodilating and vasoconstricting
substances impairs regulation of vascular tone. As production or availability of NO is
diminished, its ability to protect against vascular injury, inflammation, and thrombosis is
diminished. Normally NO inhibits leukocyte adhesion, helps maintain non-proliferative
vascular smooth muscle, and limits platelet aggregation (Sztnitko et al., 2003).
Unfortunately, CVD risk factors, such as hypercholesterolemia, hypertension and
diabetes, reduce endogenous defenses of the vascular endothelium and it begins to break
down. Hypercholesterolemia enhances blood leukocyte attachment to the endothelium
(Szmitko et al., 2003). This may lead to an increase in the amount of low-density
lipoproteins (LDL) that becomes oxidized. Oxidized LDL (oxLDL) activate and change
the biological characteristics of the endothelium reducing intracellular NO concentrations
(Szmitko et al., 2003). Angiotensin II, a potent vasoconstrictor associated with
hypertension, also has several negative effects. Angiotensin II, according to Wang et al.
(2003), is a key bioactive factor involved in the atherosclerotic disease process. It
inhibits NO action, elicits reactive oxygen species (ROS), increases IL-6 and monocytechemoaftractant protein-1 (MCP-1), and up-regulated VCAM-1 on the endothelium
(Szmitko et al., 2003). According to Szmitko et al. (2003) newer risk factors such as hsCRP also appear to promote endothelial dysfunction. Hs-CRP quenches the production
of NO and diminishes its bioactivity. All these endothelial alterations enhance
inflammation (Szmitko et al., 2003).
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Once endothelial cells undergo inflammatory activation, areas of the arterial
endothelium start to express selective adhesion molecules on their surface (Charo, 1992;
Libby, Ridker, and Maseri et al., 2002; Szmitko et al., 2003). These adhesion molecules
bind to various classes of leukocytes (Libby, Ridker, and Maseri et al., 2002). Research
has identified a number of vascular endothelial adhesion molecules that can mediate
leukocyte adhesion to the endothelium in a selective manner. According to Luscinskas &
Gimbrone (1996) the primary examples are from four gene families: 1) the selectins (EP-and L-selectin); 2) the itnmunoglobulin family [ICAM-1, -2, and -3; VCAM-1;
platelet-endothelial cell adhesion molecule (PECAM-1)1; 3) the integrins (B1- and B2integrins); and 4) mucin-like adhesion molecules [P-selectin glycoprotein ligand-1
(PSCG-1)]. Once activated, endothelial cells can also synthesize an array of leukocyte
chemoattractants, such as members of the chemokine gene family [MCP-1 and
interleukin-8 (IL-8)], platelet-activating factor (PAF), and leukotriene B4 (LTB4)
(Luscinskas & Gimbrone, 1996; De Caterina et al., 2000). Chemoattractants such as
LTB4 and PAF act broadly on neutrophils, eosinophils, basophils, and monocytes,
whereas others such as MCP-1 and IL-8 are selective for leukocyte subsets (De Caterina
et al., 2000). Multiple receptor-ligand pairs appear to function in a sequential manner (an
adhesion cascade) to allow the initial interactions of leukocytes with the endothelial
lining. This initial interaction is called phase I or the rolling phase. The initial rolling
interactions are weak and reversible unless the leukocytes are activated to undergo stable
adhesion. This stable adhesion is considered phase II or the arrest and spreading phase.
During the rolling interval, chemoattractants derived from the endothelium, such as
MCP-1 and IL-8, appear to critically affect adhesion of mononuclear leukocytes by
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triggering the activation of Bl- and B2-integrin (Devaraj, Kumaresan, and halal, 2003;
Luscinskas & Gimbrone, 1996, Wang et al., 2004). Once the integrins are activated a
dramatic increase in monocyte adhesivness is seen, presumably via binding to ligands,
such as ICAM-1 and -2 and VCAM-1. This results in stable arrest (phase II). The
monocyte flattens and extends pseudopods toward the intercellular junctions between
neighboring endothelial cells. The monocyte ultimately transmigrates through the
endothelial junctions into the extravascular space (phase III, transmigration). PECAM-1
is involved in this last step, along with B1- and B2-integrins (Charo, 1992; Luscinskas &
Gimbrone, 1996). This entire process takes place within minutes for monocytes, but
significantly longer for T cells. Monocytes and lymphocytes can directly influence the
endothelium and each other once inside the interstitial space by secreting growth factors,
chemotactic substances, and cytokines such as interleukin-4 (IL-4), interferon-y (IFN-y),
interleukin-10 (IL-10), interleukin-2 (IL-2), and interleukin-12 (IL-12) (Luscinskas &
Gimbrone, 1996).
Blood-derived inflammatory cells participate in and perpetuate a local
inflammatory response once they have resided in the arterial wall (Libby, Ridker, and
Maseri et al., 2002). Native LDL may be oxidized by resident vascular cells, such as
endothelial cells, smooth-muscle cells, and macrophages, after it becomes trapped in the
subendothelial space. The oxLDL can stimulate monocyte chemotaxis along with
endothelial dysfunction and injury (Ross, 1999). Endothelial cells are activated by the
oxLDL to express MCP-1, which attracts monocytes into the subendothelial space from
the vessel lumen (Navab et al., 1991). Once inside the intima monocytes differentiate
into macrophages. Macrophages begin to express scavenger receptors, such as SR-A,
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CD36, and LOX-1, which allows them to ingest the oxLDL and become foam cells
(Szmitko et al., 2003). Macrophage colony-stimulating factor (M-CSF) along with MCP1 contributes to the monocyte differentiating into the macrophage foam cell. T-cells also
produce inflammatory cytokines (INF-y and TNF-B), which in turn stimulate
macrophages, vascular endothelial cells, and smooth muscle cells (SMCs).
As the process continues, macrophages and foam cells release fibrogenic
mediators (i.e. peptide growth factors). These mediators can promote SMC replication
and contribute to proliferation and production of dense extracellular matrix, creating a
fibrous cap (Libby, Ridker, and Maseri et al. 2002; Ross, 1999). IL-8, which is present in
macrophage dense areas of the atheroma, can also induce proliferation and migration of
SMC (Devaraj, Kumaresan, and Jialal, 2003). The vascular smooth muscle cells
(VSMC) that accumulate in the intima play a key role in the development of the arterial
lesion. These cells synthesize collagen that stabilize the fibrous cap. However, as the
lesion progresses VSMC apoptosis occurs, contributing to plaque vulnerability.
Blaschke et al. (2004) found that hs-CRP induced VSMC apoptosis in cultured
human VSMCs via up-regulation of growth arrest-and DNA damage- inducible gene 153
(GADD153) mRNA expression. According to Blaschke et al. (2004) GADD153 is
involved in growth arrest and apoptosis in both vascular and non-vascular cells. Using
immunohistochemistry, Blaschke et al. (2004) were able to identify hs-CRP deposition in
the deeper parts of the intima adjacent to the media and in the plaque shoulder region in a
fibrous cap atheroma. They were also able to identify VSMCs as hs-CRP containing
cells with a-Smooth muscle actin stain.
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As the atherosclerotic disease process continues the plaque becomes more
unstable. Foam cells and macrophages produce metalloprotienases that contribute to
matrix degradation. Hence, they contribute to both growth of the lesion and plaque
instability. IL-8 also contributes to the breakdown of the fibrous cap as it begins to
inhibit tissue inhibitor of metalloproteinase (TIMP) (Devaraj, Kumaresan, and Jialal,
2003). As the proteolytic enzymes degrade the collagen in the fibrous cap, it becomes
thin, weak, and susceptible to rupture (Libby, Ridker, and Maseri et al., 2002). Tlymphocytes are also involved in the degradation of the fibrous cap. They produce INFy, which can halt the synthesis of collagen by the SMC, thereby limiting the renewal of
collagen.
The thinning fibrous cap is now more vulnerable to rupture (Ross, 1999). Once
the plaque has been disrupted excessive apoptosis of the VSMCs can increase
thrombogenicity. The VSMCs produce active thrombin, which activates platelet
adherence (Devaraj, Kumaresan, and halal, 2003). Macrophages produce tissue factor,
which is a major procoagulant and can trigger thrombosis. Thrombus formation can lead
to vessel occlusion and trigger a cardiovascular event.
It has been thought for some time that inflammatory mediators are important
regulators of the atherosclerotic disease process (Libby, Ridker, and Maseri et al., 2002),
but only recent evidence has begun to demonstrate the functional role of hs-CRP. HsCRP is now emerging to be more than just a biomarker. It is being examined for its
functional role in the atherosclerotic disease process.
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D. Hs-CRP, Atherosclerotic Biomarker or Contributor
Recent evidence suggests that hs-CRP may directly promote atherosclerosis.
Traditionally, it has been thought that hepatocytes, during the acute-phase response,
produced hs-CRP exclusively. Recent evidence, however, suggests that hs-CRP is being
produced by the atherosclerotic arteries themselves. Calabro, Willerson, and Yeh (2003)
found that human coronary artery SMCs could produce hs-CRP when incubated with
inflammatory cytokines: TNF-a, IL-6, interleukin-1B (IL-1B) or a combination of IL-1B
and IL-6. Calabro, Willerson, and Yeh (2003) concluded that locally produced hs-CRP
participated directly in atherogenesis and cardiovascular complications.
According to Szmitko et al. (2003), hs-CRP provokes inflammation and
endothelial dysfunction via multiple mechanisms. It appears to reduce transcription of
endothelial nitric oxide synthase (eNOS) and destabilizes eNOS mRNA, which leads to a
diminished release of nitric oxide (NO). This is turn reduces protection against vascular
injury and inflammation. Hs-CRP causes further disruption to endothelial homeostasis
by stimulating the release of ET-1 and IL-6, by up-regulating adhesion molecules
(ICAM-1, VCAM-1, selectins), and by stimulating MCP-1. Hs-CRP also appears to
increase the expression of plasminogen activator inhibitor-1 (PAI-1), a serine protease
inhibitor. PAT-1 inhibits tissue plasminogen activator (tPA), thereby regulating
fibrinolysis in atherothrombosis. (L. Li, Roumeliotis, Sawamura, and Renier, 2004; Wang
et al. 2004). Nuclear factor-KB (NF- KB), a key transcription factor involved in
controlling gene expression concerning the inflammatory response, also appears to be
affected by hs-CRP (J. Li, Fang, Chen, Chen, and Lee, 2004). Preliminary observations
from Szmitko et al. (2003) indicate that hs-CRP up-regulates NF- KB. NF- KB remains
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inactive in the cytoplasm of monocytes, lymphocytes, smooth muscle cells, and
endothelial cells, until it is stimulated (Li et al. 2004). Once stimulated NF- KB
transcriptionally activates several proatherosclerotic genes (Szmitko et al., 2003): IL-1,
IL-6, IL-8, interferon, TNF-a, endothelial cell adhesion molecule-1 (ECAM-1), ICAM-1,
and VCAM-1 (Li et al., 2004). Activated NF- KB has been found in the coronary
vasculature and in atherosclerotic lesions, even in early stages.
According to Ghanim et al. (2004), an increase in NF- KB in the nucleus and a
decrease in its inhibitors I KB-a and/or I KB-B describe inflammation at the cellular level.
Ghanim et al. (2004) examined the proinflammatory state of peripheral blood
mononuclear cells (MNC) in obese subjects. They found that transcriptional activity was
increased in IL-6, TNF-a, migration inhibitor factor (MIF), and matrix metalloproteinase9 (MMP-9) genes of healthy non-diabetic obese female participants when compared to
normal-weight controls. This increase in transcriptional activity was reflected by
increased levels of mRNA, which is consistent with increased binding of intranuclear
NF- KB. Obese participants had significantly higher (p<0.05) DNA binding of the
transcriptionally active form of NF- KB (p65/p50) in MNCs compared with lean
participants. Significant correlations between NF- KB binding and hs-CRP was also seen.
L. Li, Fang, et al. (2004) also found a positive correlation between serum levels of
hs-CRP and NF- KB activity. These researchers investigated NF- KB activity in white
blood cells from patients (n = 33) with coronary heart disease (CHD). Participants with
unstable angina had an increase in NF- KB activity and elevated hs-CRP levels compared
to those with stable angina. Li et al. (2004) concluded that hs-CRP and NF- KB are
useful in detecting vulnerable plaque and unstable angina.
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Wang et al. (2005), like other researchers (Ghanim et al. 2004; L. Li, Fang et al.
2004; Szmitko et al., 2003), concluded that hs-CRP can significantly influence vascular
endothelial gene expression and therefore play a functional role in atherogenesis. In
order to investigate the effects of hs-CRP on vascular endothelial cell gene expression,
Wang et al. (2005) incubated human vascular endothelial cells with hs-CRP in
concentrations ranging from 0-10 ug/ml. They found that eleven genes (IL-8, PAI-1,
MCP-1, Fibronectin-1, Connexin-43, ZF9, Activin A, EXT1, Cited2, SORL-1, and
Gravin) increased and six genes (PIN, AnnexinA 1, MAT2A, WRB, RCN1, and TEB4)
decreased on their mRNA levels. The IL-8 gene was the most significantly up-regulated
gene, with a 13.6-fold increase. This up-regulation began as early as three hours after
incubation with hs-CRP and continued for over 24 hours. This is a significant find
because IL-8 is involved in many aspects of the atherosclerotic disease process. As
stated by Devaraj, Kumaresan, and halal (2003), IL-8 mediates recruitment and
transmigration of phagocytes across the endothelium and appears to be a powerful trigger
for monocyte adhesion to the endothelium. Wang et al. (2005) found that monocyte
adhesion to the endothelium was enhanced 2-fold (p<0.01) by hs-CRP. They also found
that the response was partially blocked by an anti-IL-8 antibody. IL-8 is also important
during later stages of atherogenesis. It is induced by lipid loading of macrophages and is
found in macrophage-rich areas of human coronary atheroma. It stimulates proliferation
and migration of VSMCs and inhibits tissue inhibitor of metalloproteinase (TIMP) seen
during later stages of the disease (Devaraj, Kumaresan, and Jialal, 2003). Hence, IL-8 is
involved in the building up and breaking down of the atheroma's fibrous cap.
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Devaraj, Kumaresan, and halal (2003) also found that hs-CRP effected IL-8
expression and synthesis. Like Wang et al., (2005), Devaraj, Kumaresan, and halal
(2003) incubated human aortic endothelial cells (HAEC) with hs-CRP. Western blotting
was used to assay IL-8 protein, and B-actin was used as a loading control. Devaraj,
Kumaresan, and halal (2003) found that hs-CRP (5 to 50 ug/ml) increased IL-8 protein
levels in a dose-dependent manner. Incubation with hs-CRP also resulted in a dosedependent increase in IL-8 mRNA levels. Actinomycin D, a transcription inhibitor of IL8, prevented an increase in IL-8 following incubation with hs-CRP. It would appear from
these finding that hs-CRP effects IL-8 at the transcriptional level. Therefore, Devaraj,
Kumaresan, and Jialal, 2003 further investigated the effects of hs-CRP on NF-KB. They
found that hs-CRP did in fact augment NF-KB activity and that inhibitors of NF-KB
reversed the up-regulation of IL-8 by hs-CRP significantly
The induction of IL-8 expression and synthesis via up-regulation of NF-KB
activity in HAEC found by Devaraj, Kumaresan, and halal (2003) provides additional
evidence that hs-CRP has atherogenic properties. This information is valuable because it
provides a possible pathway for risk reduction. Because IL-8 is a key player in
atherosclerosis, its reduction could potentially reduce risk. Therefore, a reduction in hsCRP could possibly decrease risk, at least in part, by reducing IL-8.
As mentioned previously Wang et al. (2005) found several genes to be downregulated following incubation with hs-CRP. One of those genes was PIN, a protein
inhibitor of neuronal nitic oxide synthase (nNOS). According to Wang et al. (2005), the
nitric oxide (NO) derived from nNOS is neurotoxic during the initial phase of ischemia.
Inhibition of nNOS might decrease ischemic injury of neurons after a cerebral vascular
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accident (CVA). According to Wang et al. (2005), clinical observations support this
theory. Several studies have found that higher concentrations of hs-CRP predict worse
outcomes in CVA patients (Di Napoli, Papa, and Bocola, 2001; Winbeck, Poppert, Etgen,
Conrad, and Sander, 2002). By preventing the down-regulation of PIN, via hs-CRP
reduction, we may thereby reduce ischemic injury and improve CVA patient outcomes.
Another mechanism by which hs-CRP provokes endothelial dysfunction is via its
promotion of foam cell formation. Hs-CRP facilitates oxLDL uptake by macrophages
(Szmitko et al., 2003; Yeh & Willerson, 2003). It is well known that a crucial step in
atherogenesis is the unregulated uptake of oxLDL by vascular cells (L. Li, Roumeliotis,
Sawamura, and Renier, 2004). This uptake causes further activation of the endothelium
and changes the biological characteristics. A newly identified receptor of oxLDL is
endothelial lectin-like oxidized LDL receptor-1 (LOX-1). Accumulating evidence
suggests uptake via LOX-1 may also induce endothelial dysfunction. The binding of
oxLDL to endothelial LOX-1 decreases NO production, generates superoxide anions, and
activates NF- KB, all of which contribute to endothelial dysfunction (L. Li et al., 2004).
L. Li et al. (2004) investigated the effects of hs-CRP on LOX-1 expression,
monocyte adhesion to the endothelium, and endothelial uptake of oxLDL. They
incubated human aortic endothelial cells (HAECs) with hs-CRP. Hs-CRP, in
concentration of just 5 ug/mL, enhanced LOX-1 mRNA levels. Concentrations between
10-25 ug/mL produced maximal effects. L. Li, Roumeliotis et al. (2004) also found that,
through LOX-1, hs-CRP increased monocyte adhesion and uptake of oxLDL by the
endothelial cells. They concluded that increased LOX-1 expression via hs-CRP was
another mechanism by which hs-CRP promotes endothelial dysfunction.
25

Hs-CRPs proatherogenic effects extend beyond the endothelium to the VSMC.
Hs-CRP appears to stimulate VSMC, at least in part, by activating NF- KB (J. Li, Wang,
Huang, Xue, and Li, 2005) and by up-regulating angiotensin-type 1 receptors (AT i-R)
(Szmitko et al. 2003; Wang et al. 2003). In concentrations known to predict
cardiovascular events, hs-CRP demonstrates up-regulation of ATi-R in VSMC. ATi-R
mediates the majority of angiotensin II effects. ATi-R up-regulation augments ROS
production, restenosis, and VSMC proliferation and migration (Szmitko et al. 2003;
Wang et al. 2003). Wang et al. (2003) examined the effects of human VSMCs treated
with human recombinant CRP (0 to100 ug/mL). They found that AT i-R mRNA and
protein expression were up-regulated. AT i -R number was also increased on VSMCs.
VSMC migration and proliferation was promoted by hs-CRP and hs-CRP increased
production of ROS.
Current research is beginning to support the theory that hs-CRP is more than just
a biomarker for CVD. Hence, therapies directed at its reduction appear to be valuable.
Therapies, such as aspirin or statin-class medications, have been shown to reduce hsCRP. Obisesan et al. (2004) stated that statin therapy has been shown to decrease hsCRP by 13-17%. Ridker et al. (2005) found that individuals with low hs-CRP
concentrations following statin therapy had better clinical outcomes compared to those
with higher hs-CRP concentrations. They found that event-free survival was significantly
improved in acute coronary syndrome patients that reduced hs-CRP levels to less than 2
mg/L following statin therapy. This effect was seen at all levels of LDL. Ridker et al.
(2005) stated, "Our data also provide support for ongoing efforts to find agents capable of
lowering CRP as a potential method of reducing vascular risk". Controversy,
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unfortunately, exists as to whether statin therapy is appropriate in primary prevention in
individuals with high hs-CRP, but normal lipid levels. Therefore, lifestyle therapy may
be more appropriate in these individuals. Physical activity, for example, may actually
reduce hs-CRP to a greater extent than pharmacological therapies.
E. Hs-CRP and Physical Activity
It is well known that regular physical activity reduces the risk of cardiovascular
disease (Erikssen et al., 1998), and recent studies have found an association between
physical activity and hs-CRP. Regular exercise appears to diminish the acute phase
reaction, which suggests suppression of the inflammatory response (Mattusch, Cufaux,
Heine, Mertens, and Rost, 2000). Intervention studies have shown reductions in hs-CRP
in exercise groups compared to controls. Geffken et al. (2001) found an inverse
relationship between hs-CRP and regular physical activity among healthy elderly 65
years) participants (n = 5,201 participants, 2,961 females, 2,239 males). Mattusch et al.
(2000) found that nine months of endurance training reduced hs-CRP levels by 31%
when compared to non-training controls. Following six months of supervised exercise
training Smith, Dykes, Douglas, Krishnaswamy, and Berk (1999) observed a 35%
reduction in hs-CRP in individuals (n = 43) at high risk of ischemic heart disease.
Although these studies supply evidence that hs-CRP levels are reduced by regular
physical activity, they lack either generalizability, fail to adjust for body weight and other
confounding variables, or fail to account for drop outs. For example, Mattusch et al.
(2000) failed to control for known confounding variables such as the presence of
cardiovascular disease, race, smoking, age, diabetes, hypertension, and body mass index,
which improved the quality of the study.
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Mattusch et al. (2000) measured hs-CRP before and after nine months of
marathon training in fourteen participants. During the training, distance run increased
significantly as did the subjects aerobic capacity. Following training hs-CRP levels were
reduced (1.19 mg/L to 0.82 mg/L). This was an unexpected result since intense exercise
has been associated with inflammation of muscles and tendons. Mattusch et al. (2000)
concluded that a decrease in hs-CRP following intense endurance training suggests that
intense regular exercise has a systemic anti-inflammatory effect.
Mattusch et al. (2000) provided preliminary intervention data showing reduced
hs-CRP levels following training. Results of this study are limited to males training for a
marathon, therefore we can not generalize the results. Data from several participants was
thrown out and not used in the statistical analyses, which could have created bias.
Mattusch et al. (2000) failed to control for diet. Several dietary factors influence hs-CRP
levels. Omega-3 fatty acid consumption for example, may reduce hs-CRP level
(McCarty, 1999). Mattusch et al. (2000) also failed to adjust for body weight.
Reductions in body weight can reduce hs-CRP (Pearson et al., 2003). Hence, we don't
know if the reduction in hs-CRP were due to exercise independently.
In many individuals inflammation is a result of obesity, particularly central
obesity (Ridker, 2003). Many researchers have found strong positive associations
between hs-CRP and waist girth, body fat mass, and visceral adiposity. LaMonte et al.
(2002) found significant correlation between hs-CRP and waist girth, BMI, insulin,
fitness level, and triglycerides. They examined the relationship between plasma hs-CRP
and fitness level in 45 Native American (NA), 44 African American (AA), and 46
Caucasian (CA) women. Hs- CRP was measured following a 12-hour fast and 24-hour
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abstinence from exercise and smoking. Duration of a maximal treadmill test was used to
quantify fitness. A general linear model was used to analyze differences in hs-CRP
concentrations across categories of race, fitness, and BMI. Treadmill exercise times were
adjusted for age with linear regression and used to quantify fitness level. LaMonte et al.
(2002) found hs-CRP was decreased in those with higher fitness levels and was increased
in those with higher BMI and waist girth. They also found that hs-CRP levels varied by
race. Lower hs-CRP levels were observed across tertiles of race-specific treadmill times
in CA and NA, but not in AA after adjusting for BMI, smoking, diabetes, and estrogen
status. The mechanisms for racial differences were unknown.
Rawson et al. (2003) found that BMI, not physical activity was associated with a
reduction in hs-CRP. They measured hs-CRP five times over one year and examined the
effects of BMI and both current and previous year physical activity in healthy men and
women (n = 109). Current physical activity was measured using a telephone interview
with a standardized interview script and a Baecke questionnaire was used to assess the
previous year's physical activity. Over the course of the study physical activity
increased, while BMI and hs-CRP remained unchanged. Only BMI was significantly
related to hs-CRP when current physical activity, BMI, age, gender, and smoking were
included in the statistical model. Current physical activity was similar when grouped by
BMI (obese, overweight, normal) and was unrelated to hs-CRP. It may be that BMI was
measured with greater reliability than physical activity, hence the association between
BMI and hs-CRP was stronger than the association between physical activity and hsCRP. Rawson et al. (2003) also found that as BMI increased, levels of hs-CRP increased.
The lack of an association between physical activity and hs-CRP was surprising, as other
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studies have found reductions in hs-CRP with increased physical activity. Discrepancies
between this study and others could have resulted from cohort differences, subject
screening and study design. For instance, the participants in Geffken et al. were older (79
years vs. 49 years). Hs-CRP is affected by age (Pearson et al., 2003). The study
conducted by Smith et al. (1999) assessed hs-CRP in participants at risk for
cardiovascular disease taking lipid-lowering medications. Some lipid lowing medications
are known to reduce hs-CRP levels (Pearson et al., 2003). The cohort in the Rawsen et
al. study was largely sedentary throughout the study while the participants in the Smith et
al. and Geffken et al. studies were more physically active. In order to reduce hs-CRP,
higher levels of physical activity may be needed when BMI remains stable. Respondent
bias could also have lead to discrepancies between this study and others. It is well known
that retrospective judgments can be biased. A number of factors influence retrospective
data, such as the length of time since the event being recalled and specificity versus
generality of information needed. Recalling physical activity over the past year may have
been difficult, resulting in greater respondent error. If the survey used asked the
participants specific events, the chance of inaccurate recall would have increased.
Interviewer technique could also have introduced bias.
Physical activity has also been associated with reduced insulin resistance and
reduced visceral obesity (Tracey, 2001). According to an editorial written by Tracey
(2001) the Insulin Resistance and Atherosclerosis Study (IRSA) reported a strong
association between insulin resistance and visceral adiposity. According to Tracey the
study concluded that central obesity was the critical correlate of hs-CRP. Other
researchers have found cardiorespiratory fitness levels to be inversely associated with hs30

CRP independent of body mass index (BMI). Wannamethee et al. (2002) examined the
association between regular leisure-time activity and hemostatic and inflammatory
variables. They found that physical activity was significantly and inversely associated
with several hemostatic and inflammatory variables, including hs-CRP. This association
persisted after adjustment for age, BMI, smoking, alcohol, and preexisting CVD.
Church et al. (2002) also found an association between cardiorespiratory fitness
and hs-CRP independent of BMI. Cardiorespiratory fitness was assessed by a maximal
treadmill test using a modified Balke protocol. They adjusted for weight and within
weight categories. Participants (n = 722) were part of the Aerobic Center Longitudinal
Study (ACLS), an epidemiological study of patients who received a preventive medical
examination at the Cooper Clinic in Dallas, Texas. Church et al. calculated median and
adjusted geometric mean hs-CRP levels, odds ratios of elevated hs-CRP across five levels
of cardiorespiratory fitness, and percentages of individuals with hs-CRP 2 mg/L. They
adjusted for age, BMI, smoking habit, vitamin use, statin medication, use of aspirin, and
known inflammatory disease, CVD, and diabetes. An inverse association was found
across fitness levels. Hs-CRP was highest in the lowest fitness quintile and lowest in the
most fit quintile. Results were similar when the hs-CRP-fitness relationship was
examined within categories of body fatness (normal weight, overweight, and obese).
Church et al. (2002) had a number of strengths in their study. They used
metabolic equivalents (METs) as an objective measure of cardiorespiratory fitness, they
had a large sample size, a thorough medical history, and in depth information on
smoking, medication and vitamin use. Another important strength was the examination
of fitness and hs-CRP with different levels of body composition and fat distribution.
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Although this study had numerous strengths it also had limitations. Diet was not
evaluated. Diet may influence hs-CRP and those that exercise regularly often have
healthier diets than non-exercisers. The population studied was predominantly white,
middle-to-upper class, which limits the ability to generalize the results. Although this
homogenous group reduces external validity it improved internal validity by reducing the
likelihood of confounding variables.
F. Possible Mechanisms for Reduced Hs-CRP Following Training
Several theories exist as to how regular exercise reduces hs-CRP and the
inflammatory process. Mattusch et al. (2000) suggested that hs-CRP levels were
reduced, at least in part, due to enhanced antioxidative defense mechanisms seen after
regular exercise training. It has been reported that well trained athletes have increased
activity in muscular and erythrocytic antioxidative enzymes. Animal studies have also
shown improved antioxidant defense mechanisms after exercise training. It may be that
enhanced antioxidative protection reduces the production of IL-6 and other cytokines in
the exercising muscle (Mattusch, 2000).
Church et al. (2002) also proposed interleukins as a potential pathway. Evidence
suggests that TNF-a and IL-6 are involved in hs-CRP production. TNF-a and IL-6 are
released from adipose tissue, particularly visceral sites. Their release is augmented by
the down-regulation of sympathetic stimulation via regular physical activity. This may
lead to a reduction in hs-CRP. TNF-a stimulates the production of IL-6 and IL-6
stimulates the production of hs-CRP. Unlike a single bout of exercise which may
increase plasma levels of IL-6, IL-1B, and other associated inflammatory markers,
repeated exercise training appears to lower basal plasma interleukin concentrations.
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TNF-a also appears to be reduced following regular exercise training. Reduction in TNFa and IL-6 have been found independently of weight loss, hence, TNF-a and IL-6 may be
responsible for reduced hs-CRP in fit individuals (Church et al., 2002).
Smith et al. (1999) found that exercise reduced TNF-a. These researchers
examined the possibility that long-term exercise could favorably alter the production of
cytokines with atherogenic and atheroprotective properties. Cytokines with atherogenic
properties include IL-1, TNF-a, and IFN-y. Cytokines with atheroprotective properties
include IL-4, IL-10, and transforming growth factor beta (TGF-B). Smith et al. (1999)
measured the effects of exercise on the production of these cytokines by blood
mononuclear cells. They also examined the effects of exercise on serum levels of hsCRP. Following six months of moderate intensity training, blood mononuclear cell
production of cytokines was attenuated, while the production of cytokines with
atheroprotective properties was increased. These changes were proportionate to the time
participants spent performing repetitive lower-body exercises, which would suggest a
dose-response relationship. A reduction in hs-CRP accompanied the changes in immune
cell function. This could indicate a systemic reflection of decreased IL-la and TNF-a
production. These alterations were independent of aspirin or other medication use,
dieting, weight loss, or smoking cessation. Smith et al. (1999) also found a significant
attenuating effect on IFN-y and TNF-a following training. Because both of these
cytokines have been identified in early and advanced atherosclerotic lesions this is a
favorable sign in persons at risk of developing cardiovascular disease. Endothelial cells,
monocytes, macrophages, and smooth muscle cells are activated by these cytokines,
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hence they contribute to leukocyte recruitment, endothelial cell procoagulant activity,
LDL oxidation, and foam cell formation in atherosclerotic lesions.
Few studies have examined the effects of exercise on hs-CRP therefore the
mechanisms remain largely unknown at this time. Further studies are clearly warranted.
G. Conclusions
There is increasing evidence that atherosclerosis is a dynamic and progressive
disease resulting from the combination of inflammation and endothelial dysfunction.
Advances in basic and experimental science have established that inflammation is
involved in mediating all stages of this disease from initiation through progression and,
ultimately, to atherosclerotic plaque complications (Pearson et al., 2003; Libby, Ridker,
& Maseri, 2002). These new findings not only provide a link between risk factors and
the mechanisms of atherogenesis, but the connection between inflammation and
atherosclerosis also provides predictive and prognostic information (Libby, Ridker, &
Maseri, 2002). Several markers of the inflammatory cascade have been examined as
potential tools in the prediction of cardiovascular events. Hs-CRP is one of those
markers and has generated much interest (Szmitko et al., 2003). Emerging evidence
suggests that hs-CRP is one of the strongest independent predictors of cardiovascular
events and may play a functional role in the atherosclerotic disease process (Szmitko et
al., 2003; Yeh & Willerson, 2003). It appears to be even better than low-density
lipoprotein (LDL) cholesterol at predicting cardiovascular events. This new information
is profound and is beginning to change the way we screen and manage patients (Yeh &
Willerson, 2003).
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It is well known that regular physical activity is associated with lower risk of
coronary heart disease, stroke, and cardiovascular mortality. Although the mechanisms
are unclear, evidence suggests that physical activity modifies the inflammatory process.
Recent studies have demonstrated an inverse relationship between inflammatory markers
such as hs-CRP and physical activity. At this time only a handful of studies have
examined the effects of exercise on hs-CRP and results are conflicting. More research is
clearly needed to assess the relationship between hs-CRP and physical activity.
Questions remain regarding: (1) the type and intensity of exercise needed to reduce hsCRP, (2) whether the association seen between physical activity and lowered hs-CRP is
mediated by reduced body fat, and (3) whether fitness level modifies hs-CRP in those
with the metabolic syndrome.
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CHAPTER 3
METHODS
A. Overview
The purpose of this study was to examine the relationship between hs-CRP,
metabolic syndrome and physical activity. Understanding this relationship will provide
insight into the potential of physical activity as a therapeutic option to reduce
cardiovascular disease risk. This study relied on a cross-sectional, retrospective analysis
of an archival database. Study participants were obtained from a pool of 1,072 men and
women patients at the Center of Health Promotion (CHP) at Loma Linda University. Of
the 1,072 pool, 173 individuals met the inclusion criteria and were the subjects of the
study. Any missing data variables were imputed using the maximum likelihood method
(EM) in SYSTAT version 10; SPSS©2000. Simple regression/correlation analysis was
used to evaluate the relationships between log (CRP) and each of the relevant variables:
VO2max (ml-kg-l•min-1), metabolic syndrome, and the physical activity status. The
following relationships were explored: (1) hs-CRP and metabolic syndrome
characteristics, (2) hs-CRP and VO2max, (3) VO2max and metabolic syndrome
characteristics, and (4) VO2max and physical activity status. Pearson Chi-square analysis
was used to determine if a threshold level of physical activity was associated with hsCRP changes.
B. Subjects
Study participants were selected from a pool of 1,072 men and women that
underwent a medical exam at the Center for Health Promotion (CHP). The CHP is a
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preventive health clinic that provides preventive medicine services to Southern California
communities. Participants were, at the time of measurement, residents of Southern
California's Inland Empire residing in San Bemadino and Riverside counties.
Participants were included in this study if they: (1) underwent a medical exam at the CHP
at Loma Linda University, which included blood pressure screening and blood analysis•
(hs-CRP, lipid profile and fasting blood glucose), (3) completed a Comprehensive
Personal Wellness Profile (PWP) questionnaire regarding their medical history and
lifestyle health practices (Wellsource Inc., Clachamus, OR), (4) attained 85% of
estimated maximal heart rate on a Bruce protocol treadmill stress test at the CHP, and 5)
were able to give informed consent. Failure to meet all of these criteria resulted in
exclusion from the study. A total of 173 patients fulfilled the criteria and were included
as the subjects of this study.
C. Measurement Variables
Cardiorespiratory fitness level was assessed via maximal oxygen uptake
(V02max, expressed in ml.kg-1-min-1) estimated from a Bruce protocol treadmill stress
test. The PWP questionnaire was used to collect information regarding the participant's
medical history and lifestyle behaviors such as: smoking habits, alcohol intake patterns,
eating habits, stress and coping patterns, social health, and physical activity status.
Several questions were asked regarding the participant's physical activity status.
Participants were asked about their current physical activity status under the headings of:
(1) no regular exercise program, (2) occasionally walk for pleasure, (3) regular exercise
in work or recreation requiring modest physical activity such as golf, yard work,
calisthenics, up to one hour per week, (4) regular exercise in work or recreation requiring
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modest physical activity such as golf, yard work, calisthenics, more than one hour per
week, or (5) more active physical exercise (brisk walking, jogging, swimming). If the
participant answered yes to the last question they indicated how much time was spent
engaging in that activity each week.
Quest diagnostics performed the blood chemistry analyses. They annually
perform over 100 million personal health tests, over 250 million diagnostic laboratory
tests, and more than 6.5 million gene-based tests. They are CLIA Certified and their
main laboratories are College of American Pathologists accredited. Plasma CRP
concentrations were measured with the Dade Bering BN II high-sensitivity immunoassay
(Dade Behring, Inc. IL). Fasting glucose were performed on the Olympus AU5400
Analyzer (Olympus America Inc., NY). Total cholesterol and triglyceride analyses were
performed on the Olympus AU5400 Analyzer, while HDL-cholesterol was performed on
a Roche Analyzer (Roche Molecular Systems Inc., CA).
Participants had their resting blood pressure measured by auscultation. Standard
procedures outlined by the American Medical Association were followed (Reeves, 1995)
Weight was measured on a standardardized physician's balance beam scale and
stadiometer. BMI (weight (kg)/height (m)2) was also calculated for each.
Although the definition of Metabolic Syndrome has not been agreed upon
internationally, a working definition continues to be used (Ford, Giles, and Mokdad,
2004; Kahn, Buse, Ferrannini, and Stern, 2005). Our definition utilizes criteria set forth
by both the WHO and the U.S. National Cholesterol Education Program Adult Treatment
Panel III (ATP III) guidelines (The Expert Panel, 2001; Kahn, Buse, Ferrannini, and
Stern, 2005). Participants had to meet at least three of the following variables in order to
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be labeled as having metabolic syndrome: (1) blood pressure 130/85 mm Hg, (2) HDLC <40 mg/di for males, <50 mg/di for females, (3) fasting blood glucose 110mg/d1, (4)
elevated TG 1.50 mg/di, and (5) BMI ?_30kg/m2. Due to the retrospective design of this
study and the lack of waist circumference measurements we chose to use BMI
WOkg/m2) as our measure of obesity rather than waist circumference. The WHO
definition utilizes 30kg/m2 as criteria for obesity.12
D. Data Analysis
A total of 173 patients fulfilled the inclusion criteria and were included as the
subjects of this study. Any missing data variables were imputed using the maximum
likelihood method (EM) in SYSTAT version 10; SPSS©2000. Because the percent body
fat variable required over 100 imputations to fill in all of the missing data it was not used
in any analyses. The distribution of hs-CRP, the dependent variable of greatest interest,
was positively skewed. Therefore, a log transformation was applied to hs-CRP values for
all analyses. Simple regression/correlation analysis was used to evaluate the relationships
between log (CRP) and each of the relevant variables: VO2max (ml•kg-1•min-1 ),
metabolic syndrome, and the physical activity status. The following relationships were
explored: (1) hs-CRP and metabolic syndrome characteristics, (2) hs-CRP and VO2max,
(3) VO2max and metabolic syndrome characteristics, and (4) VO2max and physical
activity status. Pearson Chi-square analysis was used to determine if a threshold level of
physical activity was associated with hs-CRP changes.
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E. Power Analysis
When designing the study a medium effect size was assumed. Power analysis
was conducted using the statistical software GPO WER (Faul & Erdfelder, 1992).
Multiple regression analysis was the statistical test used to determine power along with a
medium effect size (0.15), an alpha of 0.05, and power of 0.80. The total sample size
needed according to the GPO WER analysis was 131 participants.
F. Limitations
The proposed study has several limitations: (1) reporting bias, (2) health habits of
regular exercisers, (3) failure to control physical activity prior to blood draw, and (4) lack
of detailed medication history prior to blood draw. Participants may have embellished
when filling out the physical activity portion of the PWP. This respondent bias could
threaten the studies validity.
People that exercise regularly may also engage in other positive health behaviors,
thereby reducing hs-CRP levels. Regular exercisers, for example, may have healthier
diets than those that do not exercise regularly (Church 2002). This could influence their
hs-CRP levels. In addition to healthier eating habits, regular exercisers may have reduced
stress, anxiety, and depression (Petruzzello, Landers, Hatfield, Kubitz, and Salazar, 1991;
Plante, Unger, Hutchinson, and Faigenbaum, 1990) compared to non-exercisers. Mental
state may influence markers of inflammation (Appels, Bar, Bar, Bruggeman, and
DeBaets, 2000). According to Black (2003), an acute phase reaction may be induced by
stress alone. IL-6 is the central mediator of the acute phase reaction and it facilitates the
production of several acute phase proteins, including hs-CRP. Hence, if a person
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exercises regularly, thereby reducing stress, he or she may in turn decrease hs-CRP levels
independently of exercise.
Intense exercise leads to increased inflammation, hence hs-CRP levels will be
elevated (Mattusch et al. 2000). The participants were not instructed to refrain from
exercising prior to the blood draw. If a participant engaged in some form of exercise
prior to the blood draw hs-CRP levels could have been transiently elevated, thereby
affecting the study's validity.
Research is finding that certain medication may also influence hs-CRP values.
Medications such as statins, fibrates, and niacin appear to reduce hs-CRP, while hormone
replacement therapy appears to elevate hs-CRP levels (Pearson et al., 2003). The PWP
does not provide detailed medication history. Lack of this knowledge could affect
validity.
G. Research Ethics
Risk to participants is minimal. In order to protect participant confidentiality
individual data will be coded and sorted by identification numbers. The list matching
names and identification numbers will be stored separately from the data and both will be
kept in locked filing cabinets. The identity of the participants will be known to the
principal investigator, co-investigators, and statistical consultant. Signed consent forms
will be kept in a locked storage facility at the CHP at Loma Linda University. Access
will be restricted to the principal investigator, co-investigator, and designated
representatives of the Human Subjects Committee.
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The Relationship Between High Sensitivity C-Reactive Protein, Metabolic
Syndrome, and Exercise
Background—Metabolic syndrome (MetS) is characterized by three or more of
the following criteria: low high density lipoprotein (HDL), hypertriglyceridemia,
hypertension, obesity, and abnormal glucose. High sensitivity C-reactive protein (hsCRP) increases linearly with the number of MetS criteria. Both MetS and hs-CRP are
associated with increased risk of cardiovascular disease (CVD) and diabetes.
Cardiorespiratory fitness (CRF) is negatively associated with both the MetS and hs-CRP.
CRF is associated with reduced risk of diabetes and CVD.
Methods and Results—We examined the relationship between hs-CRP, MetS,
and CRF in 173 men and women. CRF was assessed using a Bruce protocol treadmill
test and expressed as maximal oxygen uptake (VO2max). Physical activity status was
also assessed via self report. Plasma hs-CRP levels were determined using standardized
immunoassay. Hs-CRP increased linearly with the number of MetS characteristics (p =
0.00022). An inverse association was found between hs-CRP and VO2max (p = 0.00008)
and between VO2max and the number of MetS criteria (p = 0.00004). VO2max was
positively associated with physical activity pattern (p = 0.00000). Subjects engaging in
2-3 hours of exercise per week had hs-CRP levels < 2.5 mg/L (p = 0.01817).
Conclusion—Higher hs-CRP levels are associated with lowered CRF and higher
number of MetS criteria. These associations are suggested mechanisms by which CRF
reduces the risk of CVD and diabetes.
Key Words: C-reactive protein II Exercise ll Metabolic Syndrome ll Atherosclerosisll
Inflammation
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The leading cause of death in the U.S. is cardiovascular disease (CVD).1 Today,
it is well known that insulin resistance plays an integral role in CVD etiology. 2-3 Certain
CVD risk factors appear to be exacerbated by insulin resistance. According to the Adult
Treatment Panel-III (ATP-III) Guidelines4 metabolic syndrome is characterized by three
or more CVD risk factors which include the following: abdominal obesity, low high
density lipoprotein (HDL) cholesterol, elevated serum triglycerides (TG), elevated resting
blood pressure, and impaired fasting glucose.1'5 The prevalence of metabolic syndrome
in adults aged

years has increased from 41 million in 1990 to approximately 55

million in 2000.6 Individuals with metabolic syndrome are at increased risk for both
diabetes and cardiovascular disease.6 Coronary artery disease, stroke, and myocardial
infarction appear to be increased nearly threefold. 7 Hence, the ATP-III report stresses
the significance of preventive therapies in these individuals.
It is well known that regular physical activity reduces the risk of chronic diseases
such as diabetes and cardiovascular disease. 8 Physical activity is also considered an
important determinant of metabolic syndrome.6 All levels of metabolic syndrome,
diabetes, and cardiovascular disease are thought to involve inflammation. Physical
activity may reduce risk, at least in part, by modifying the inflammatory process. Recent
studies have demonstrated an inverse relationship between inflammatory markers, such
as high sensitivity C-reactive protein (hs-CRP), and physical activity.9'10 Elevated hsCRP appears to be an independent predictor of both cardiovascular disease and diabetes.
Recent evidence also suggests that hs-CRP is positively associated with all metabolic
syndrome characteristics.5 Ridker et a1,5 stated that hs-CRP adds prognostic value to all
levels of metabolic syndrome. Based on these findings we sought to evaluate the
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relationship between hs-CRP, metabolic syndrome, and cardiorespiratory fitness (CRF),
expressed as maximal oxygen uptake (ml•kg-l.min-1).
Methods
Study sample
Study participants were selected from a pool of 1,072 men and women from the Center of
Health Promotion (CHP) at Loma Linda University. Participants were included in this
study if they: (1) underwent a preventive medicine health exam at the CHP, which
included blood pressure screening and blood analysis (hs-CRP, lipid profile, and fasting
blood glucose), (3) completed Comprehensive Personal Wellness Profile (PWP)
questionnaire regarding their medical history and lifestyle health practices (Wellsource
Inc., Clachamus, OR), (4) reached 85% of age predicted maximal heart rate on a Bruce
protocol treadmill stress test, and 5) were able to give informed consent. 173 subjects
met the criteria and were included in the study.
Clinical Measurements
Cardiorespiratory fitness level was assessed via maximal oxygen uptake (V02max,
expressed in ml-kg-1•min-1) estimated from a Bruce protocol treadmill stress test. The
PWP questionnaire was used to collect information regarding the participant's medical
history, and lifestyle behaviors such as: smoking habits, alcohol intake patterns, eating
habits, stress and coping patterns, social health, and physical activity status. Several
questions were asked regarding the participant's physical activity status. Participants
were asked about their current physical activity status under the headings of: (1) no
regular exercise program, (2) occasionally walk for pleasure, (3) regular exercise in work
or recreation requiring modest physical activity such as golf, yard work, calisthenics, up
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to one hour per week, (4) regular exercise in work or recreation requiring modest
physical activity such as golf, yard work, calisthenics, more than one hour per week, or
(5) more active physical exercise (brisk walking, jogging, swimming). If the participant
answered yes to the last question they indicated how much time was spent engaging in
that activity each week.
Quest diagnostics performed the blood chemistry analyses. Plasma hs-CRP
concentrations were measured with the Dade Bering BN II high-sensitivity immunoassay
(Dade Behring, Inc. IL). Fasting glucose was performed on the Olympus AU5400
Analyzer (Olympus America Inc., NY). Total cholesterol and triglyceride analyses were
performed on the Olympus AU5400 Analyzer, while HDL-cholesterol was performed on
a Roche Analyzer (Roche Molecular Systems Inc., CA).
Participants had their resting blood pressure measured by auscultation. Standard
procedures outlined by the American Medical Association were followed.11 Weight was
measured on a standardized physician's balance beam scale and stadiometer. BMI
(weight (kg)/height (m)2) was also calculated for each participant.
Definitions
Although the definition of Metabolic Syndrome has not been agreed upon internationally,
a working definition continues to be used.6'12 Our definition utilizes criteria set forth by
both the WHO (Table 1) 12 and the U.S. National Cholesterol Education Program Adult
Treatment Panel III (ATP III) guidelines (Table 2).4, 12,13 Participants had to meet at least
three of the following variables in order to be labeled as having metabolic syndrome: (1)
blood pressure 1.30/85 mm Hg, (2) HDL-C <40 mg/di for males, <50 mg/di for females,
(3) fasting blood glucose 110mg/d1, (4) elevated TG 150 mg/di, and (5) BMI
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..30kg/m2. Due to the retrospective design of this study and the lack of waist
circumference measurements we chose to use BMI WOkg/m2) as our measure of obesity
rather than waist circumference. The WHO definition utilizes .30kg/m2 as criteria for
obesity.12
Statistical Methods
Any missing data variables were imputed using the maximum likelihood method (EM) in
SYSTAT version 10; SPSS©2000. Because the percent body fat variable required over
100 imputations to fill in all of the missing data it was not used in any analyses. The
distribution of hs-CRP, the dependent variable of greatest interest, was positively skewed.
Therefore, a log transformation was applied to hs-CRP values for all analyses. Simple
regression/correlation analysis was used to evaluate the relationships between log (CRP)
and each of the relevant variables: VO2max (ml•kg-l•min-1), metabolic syndrome, and the
physical activity status. The following relationships were explored: (1) hs-CRP and
metabolic syndrome characteristics, (2) hs-CRP and VO2max, (3) VO2max and metabolic
syndrome characteristics, and (4) VO2max and physical activity status. Pearson Chisquare analysis was used to determine if a threshold level of physical activity was
associated with hs-CRP changes.
Results
The mean age of the 173 subjects evaluated in the study was 49.51 (9.8) years. Clinical
characteristics of the study participant are shown in Table 3. 8.7% of our subjects met
the metabolic syndrome criteria. As shown in Figure 1, hs-CRP increased linearly with
the number of metabolic syndrome criteria (p = 0.00022). Figure 2 describes the
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relationship between hs-CRP and VO2max. An inverse association was found between
hs-CRP and VO2max (p = 0.00008). An inverse relationship was also found between
VO2max and the number of metabolic syndrome criteria (p = 0.00004). VO2max was
positively related with physical activity status (p = 0.00000). Hence, fitness level was
increased, at least in part, by the amount of physical activity the participants engaged in.
The Surgeon General advises individuals of all ages to engage in a minimum of
30 minutes of moderate physical activity on most, if not all, days of the week to improve
health and reduce risk of chronic disease.14 The American College of Sports Medicine
(ACSM) recommends a minimum of 150 minutes per week of moderate-intensity
exercise for health benefits. 15 Our findings supports the Surgeon General's physical
activity recommendations and recommendations set by the ACSM.14'15 Subjects in our
study engaging in 2-3 hours of exercise per week had hs-CRP levels < 2.5 mg/L (p =
0.01817), which is considered low to moderate risk.
Discussion
An apparent common theme that appears to connect most of the metabolic syndrome risk
factors is inflammation (Figure 3).192122 Inflammation plays a role in elevated blood
pressure, dyslipidemia, impaired glucose tolerance, and obesity.19,21,22 The present study,
in agreement with others,5'7 found a positive relationship between the acute phase protein
(APP), hs-CRP, and metabolic syndrome characteristics. We found inverse associations
between: (1) hs-CRP and CRF level and (2) CRF level and metabolic syndrome severity.
It may be postulated that CRF reduces each of the risk factors seen in the metabolic
syndrome via a reduction in the inflammatory process.
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Several studies have found an inverse relationship between inflammatory markers
and physical activity.16-18 The proinflamatory cytokines IL-6 and tumor necrosis factor-a
(TNF-a) are involved in hs-CRP production. Regular exercise training appears to lower
basal plasma interleukin concentrations, such as IL-6, and TNF-a, 16-18 which in turn
downregulates hs-CRP production. According to Ghanim et a1,19 as transcriptional
activity of TNF-a and IL-6 is increased, intranuclear binding of the proinflammatory
transcription factor nuclear factor-kappa B (NF-KB) is increased. It is suggested that
exercise down modulates activation of NF-KB,7 thereby reducing TNF-a, IL-6, and CRP.
This reduction in inflammation may in turn reduce risk factors seen in the metabolic
syndrome.
It is well known that exercise improves blood pressure.2° This improvement is
likely due to several mechanisms, including reduced cytokines and APP. Hypertension
appears to stimulate production of cytokines such as IL-6 and other inflammatory
mediators from the endothelium. Elevated cytokines along with APPs may impair
endothelial dependent vasodilation.21'22 In addition to impaired vasodilation, chronic
cytokinemia may contribute to insulin resistance, which leads to hyperinsulinemia.
Hyperinsulinemia in turn stimulates the autonomic centers of the brain, which leads to an
increase in catecholamine secretion, hence, the strong correlation between hypertension
and insulin resistance syndrome. 21 Catecholamines, such as norepinephrine (NE), may
induce an acute phase reaction (APR). 21 Thus, atherosclerotic plaque buildup can ensue
due to the endothelial damage resulting from these events.
Numerous studies have found exercise training reduces proinflammatory
cytokines, such as IL-6, and APPs such as CRP.17-19 These reductions may in turn
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improve insulin resistance, hyperinsulinemia, and reduce NE secretion, thereby reducing
high blood pressure. Exercise may also reduce blood pressure via improved vasodilation.
Studies have found exercise enhances the action of vasodilators, such as nitric oxide
(NO).24 This may be due to the reduction in cytokines and APPs.
Another important metabolic syndrome characteristic, impaired glucose tolerance,
is also improved with regular exercise. This improvement is likely due to several
mechanisms, including reduced inflammation. Inflammation may activate NF-KB
signaling pathways via up-regulation of INF-a and IL-6, which stimulate hepatic CRP
production.22 TNF-a may then contribute to insulin resistance by increasing oxidation of
free fatty acid (FFA), stimulating additional cytokines (i.e. IL-6), inhibiting GLUT-4
transporters, harming endothelial function, and/or impairing glucose-stimulated release of
insulin by B-cells.22 Hyperglycemia induces IL-6 from macrophages and the
endothelium. 21 IL-6 appears to reduce insulin signaling at the insulin receptor substrate1 level. 19 Hyperglycemia also decreases insulin sensitivity, which appears to enhance
CRP production.21 The ensuing hyperinsulinemia stimulates IL-6 and TNF-a.
Endothelial nitric oxide synthase-mediated vasodilaiton becomes impaired via the
inflammatory cytokines and associated abnormal FFA oxidation. Reducing inflammation
may be an important mechanism by which exercise improves glycemic control. Regular
exercise has been found to increase the expression of GLUT 4 transporters25'26'27 and the
expression of insulin receptor substrate-1 (IRS-1).27 These alterations may be due in part
to a reductions in TNF-a and IL-6, respectively. Exercise has been found to improve
glucose tolerance and both peripheral and hepatic insulin sensitivity. 25,27,28 These
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improvements will likely lead to reduced cytokine and APP release, further improving
glycemic control.
Dyslipidemia, another risk factor seen in metabolic syndrome is also improved by
exercise. Exercise, particularly aerobic exercise, appears to increase HDL and reduces
TG. 25,28

Sympathetically induced cytokines depress lipoprotein lipase (LPL). 21 In

mice, TNF-a and IL-6 have been found to reduce LPL activity. 21 Exercise appears to
enhance activity of several enzymes involved in lipid metabolism, including LPL. 28
Hence, exercise may enhance LPL activity via cytokine reduction thereby improving
dyslipidemia.
The last metabolic syndrome characteristic is obesity. It is well known that
exercise has a positive effect on this risk factor as measured by BMI or body fat
percent.21 It may be that exercise reduces inflammation via a reduction in
adiposity.16,29,30,31 Exercise appears to reduce visceral adipose tissue.32 This may be an
important mechanism by which exercise reduces inflammation. It is now recognized that
adipose tissue functions in part as an immune organ.33 It secretes many
immunomodulatory factors and sends inflammatory signals known to cause insulin
resistance.32 Ghanim et all9 found increased intranuclear NF-KB binding and increased
concentrations of TNF-a and IL-6 in obese subjects. This proinflammatory state may
contribute to insulin resistance in obese individuals as well as those with the metabolic
syndrome.
In adipose tissue, TNF-a reduces the expression of the insulin receptor and causes
a reduction in tyrosine phosphorylation of the insulin receptor thereby interfering with
insulin action.19'33 Although the intracellular pathways activated by TNF-a remain to be
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established they are thought to involve NF-KB. 33 Once activated, TNF- a receptors
activate inhibitor kappa B kinase (IKK) complex, which appears to be a mediator of
insulin resistance. 33 The key catalytic subunit of the IKK complex, IKK2,
phosphorylates inhibitor kappa B. 33 This leads to NF-KB translocation into the nucleus,
which activates inflammatory target genes. 33 IKK also inactivates the insulin receptor
and IRS-1, which leads to decreased activation of phosphoinosito1-3 kinase, a second
messenger involved in the metabolic effects of insulin. 33 IL-6 also affects insulin's
metabolic effects via a reduction in insulin signaling at the insulin receptor substrate-1
leve1.19
As previously mentioned, exercise increases the expression of IRS-1.27 It may be
that exercise enhances expression of IRS-1 via a reduction in TNF-a and IL-6. Enhanced
expression of IRS-1 may reduce interference in insulin's action. It may be that exercise
reduces proinflammatory cytokines and the inflammatory response via a reduction in
body fat, particularly a reduction in visceral adiposity. In this context, the present study
has a couple important limitations. Inflammatory markers, such as cytokines, were not
measured and waist circumference was not measured.
Conclusions
Elevated inflammation and the presence of the metabolic syndrome significantly increase
the risk of CVD, diabetes, and premature mortality.34 We postulate that exercise reduces
the risk of these conditions by reducing inflammation. We found that hs-CRP and the
metabolic syndrome severity were reduced in those with a higher cardiorespiratory
fitness level. We also found that those engaging in 2-3 hours of physical activity per
week had lower hs-CRP levels (< 2.5 mg/L). Further clarification is needed to show
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whether exercise reduces risk factors, thereby reducing inflammation or whether exercise
reduces inflammation, thereby reducing risk factors. Regardless of which comes first, it
appears that exercise is an important means of reducing risk factors seen in those
individuals with metabolic syndrome. Aggressive therapeutic interventions of these
individuals are imperative. The ATP-III report strongly supports the use of exercise as
first-line therapy for the management of the metabolic syndrome.4'5 It would appear that
our research fmdings add support to this recommendation.
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Table 1. ATP Ill Clinical Identification of the Metabolic Syndrome*
Risk Factor

Defining Level

Abdominal obesity, (waist circumference)
Men

>102 cm (>40 in)

Women

>88 cm (>35 in)

Triglycerides

>150 mg/dL

HDL cholesterol
•

Men
Women

<40 mg/dL

Blood pressure

>130L85 mm Hg

<50 mg/dL

Fasting glucose
*Derived from Kahn et al.12

110 mg/dL
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Table 2. WHO Clinical Identification of the Metabolic Syndrome*
Insulin Resistance: (1 of the following)
1) Type 2 diabetes
2) Impaired fasting glucose
3) Impaired glucose tolerance
Plus any 2 of the following:
1) Elevated BP (?_140/90) or Antihypertensive medication
2) Plasma TG 50mg/dI
3) HDL <35 in men, <40 in women
4) BMI >30 &/or waist:hip ratio >0.9 in men, >0.85 in women
5) Urinary albumin >20mg/min, or Albumin:Creatinine ratio 30mg/g
*Derived from Kahn et al.12
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Table 3. Characteristics of Study Participants (Mean±SD)
Overall
(n = 173)
Age, y
49.5 ± 9.8
Weight, lbs
187.7 ± 44.9
Height, in.

68.3

BMI, kg/m2

28.14 ± 5.8

Systolic BP, mm Hg

110.0 ± 12.7

Diastolic BP, mm Hg

69.1 ± 8.6

Fasting Glucose, mg/dL

4.0

Triglycerides, mg/dL

93.6 ± 16.4
129.5 ± 83.3

Total-C, mg/dL

192.5 ± 39.9

HDL-C, mg/dL

53.4 ± 15.6

LDL-C, mg/dL

113.2 ± 36.5

Metabolic Syndrome Criteria
CRP, mg/L

0.91± 1.1
2.0 ± 2.0
45.0 ± 9.2

VO2max,

BMI indicates body mass index; HDL-C, high-density lipoprotein
choesterol; LDL-C , low density lipoprotein cholesterol; Total-C, total
cholesterol; CRP, C-reactive protein; VO2max, maximal oxygen
uptake.
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Figure 1. Relationship Between Log CRP and Metabolic Syndrome
Criteria. Distribution of log CRP levels among 173
participants according to the presence of 0, 1, 2, or 3
metabolic syndrome criteria. Box plots demonstrate
median, 25th, and 75th percentile values of log CRP.
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Figure 2. Inverse Relationship Between Log CRP and VO2max.
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Figure 1. Distribution of log CRP levels among 173 participants according to the
presence of 0, 1, 2, or 3 metabolic syndrome criteria. Box plots demonstrate median,
25th, and 75th percentile values of log CRP.
Figure 2. Inverse relationship between log CRP and VO2max.
Figure 3. A model describing the relationship between inflammation and metabolic
syndrome characteristics. IL-6 = interleukin-6, TNF-a = tumor necrosis factor-a, CRP =
c-reactive protein, BP = blood pressure, TG = triglyceride, IGT = impaired glucose
tolerance, DM = diabetes mellitus, NO = nitric oxide, ET-1 = endothilin-1, ICAM =
intracellular adhesion molecule, VCAM = vascular cell adhesion molecule, AT I R =
angiotensin type-1 receptor, MCP-1 = monocyte chemoattractant protein-1, NFKB =
nuclear factor KB, Ang. II = angiotension type II, IRS-1 = insulin receptor substrate 1,
LPL = lipoprotein lipase, SNS = sympathetic nervous system.
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CHAPTER 5
DISCUSSION

A. Discussion
Markers of inflammation have been examined as potential tools in the prediction of
cardiovascular events. Of these markers, the acute-phase reactant, high sensitivity Creactive protein (hs-CRP), has generated significant interest (Szmitko et al., 2003).
Emerging evidence suggests that hs-CRP is one of the strongest independent predictors of
cardiovascular events (Szmitko et al., 2003; Yeh & Willerson, 2003). According to
LaMonte et al. (2002), elevated hs-CRP is associated with a 2 to 5-fold increase in
cardiovascular event risk.
Although hs-CRP has been considered only a biomarker, recent evidence suggests
that it may directly promote atherosclerosis. According to Szmitko et al. (2003), hs-CRP
provokes inflammation and-endothelial dysfunction. It appears to reduce transcription of
endothelial nitric oxide synthase (eNOS), which leads to a diminished release of nitric
oxide (NO). This in turn reduces protection against vascular injury and inflammation.
Hs-CRP causes further disruption to endothelial homeostasis by stimulating the release of
endothelin-1 (ET-1) and interleukin (IL)-6, by upregulating adhesion molecules
(intracellular adhesion molecule-1, vascular cell adhesion molecule-1, selectins), and by
stimulating the chemokine monocyte chemoattractant protein-1 (MCP-1). Hs-CRP also
promotes foam cell formation by facilitating LDL uptake by macrophages (Szmitko et al.,
2003; Yeh & Willerson, 2003). Preliminary observations from Szmitko et al. (2003) also
64

indicate that hs-CRP up-regulates nuclear factor Kappa B (NF- KB), which facilitates
transcription of several proatherosclerotic genes. Hs-CRPs proatherogenic effects extend
beyond the endothelium to the vascular smooth muscle (VSM). In concentrations known
to predict cardiovascular events, hs-CRP demonstrates up-regulation of angiotensin-type
1 receptors (ATi -R) in vascular SMCs. This augments VSM proliferation, migration,
reactive oxygen species (ROS) production, and restenosis (Szmitko et al., 2003).
Observational studies have provided evidence that physical inactivity and low
cardiorespiratory fitness predict atherosclerotic cardiovascular disease (Blair et al., 1996;
Ekelund et al., 1988; Lakka et al., 1994, Laukkanen et al., 2001; Lee, Blair, & Jackson,
1999; Sandvik et al., 1993), while regular physical activity is associated with lower risk
of coronary heart disease, stroke, and cardiovascular mortality (Erikssen et al. 1998; U.S.
Department of Health and Human Services). Physical activity may reduce risk, at least in
part, by modifying the inflammatory process and reducing endothelial dysfunction.
Recent studies have demonstrated an inverse relationship between inflammatory markers,
such as hs-CRP, and physical activity (Geffken et al., 2001; Rawsen et al., 2003). Higher
levels of hs-CRP have also been associated with obesity and insulin resistance, while
physical activity has been associated with lesser degrees of obesity and insulin resistance.
Based on these findings many researchers have speculated that physical activity may be
associated with lower levels of inflammation via its inverse relationship with obesity and
insulin resistance (LaMonte et al., 2002).
Obesity and insulin resistance, along with elevated triglycerides, low HDL
cholesterol, and elevated blood pressure, are characteristics seen in metabolic syndrome
(Szmitko et al., 2003; Ridker, 2003). Inflammation plays a major role in almost all
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processes associated with metabolic syndrome. Hs-CRP levels are associated with
triglycerides, obesity, blood pressure, and fasting glucose (Ridker, 2003; Ridker, Buring,
Cook, & Rifai, 2003). Ridker (2003) examined the possible interrelationships between
metabolic syndrome, hs-CRP, and cardiovascular events in participants in the Women's
Health Study (n = 14,719). The women were aged 45 and older and apparently healthy
with no prior history of cardiovascular disease or cancer and did not have diabetes at
baseline. The participants completed data for all components of metabolic syndrome.
Ridker (2003) found a significant (p-trend < 0.0001) linear relationship between the
number of metabolic syndrome criteria and hs-CRP level (0.68 mg/L for women who met
no criteria of the metabolic syndrome to 5.75 mg/L for women who met all 5 criteria).
Our findings are in support of Ridker's findings. We too found a positive linear
relationship between hs-CRP and the number of metabolic syndrome characteristics.
According to Ford, Giles, & Mokdad (2004), physical activity is considered an
important determinant of the metabolic syndrome. Our results are in support of this
conclusion. The present study found an inverse relationship between the number of
metabolic syndrome characteristics and VO2max. In addition we found an inverse
association between hs-CRP and VO2max, which was in concordance with previous
research (Church et al., 2002; Mattusch et al., 2000; Smith et al., 1999). It may be that
high cardiorespiratory fitness (CRF) reduces metabolic syndrome risk factors via a
reduction in the inflammatory process.
Regular exercise training appears to lower basal plasma interleukin
concentrations, such as IL-6, and TNF-a, (Church et al., 2002; Mattusch et al., 2000;
Smith et al., 1999) which in turn reduces hs-CRP production. According to Ghanim et al.
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(2004), as transcriptional activity of TNF-a and IL-6 is increased, intranuclear binding of
the proinflarnmatory transcription factor NF-KB is increased. It may be that exercise
modulates activation of NF-KB, (Aronson, 2004) thereby reducing TNF-a, IL-6, and CRP.
This reduction in inflammation may in tun reduce cardiovascular disease risk factors
seen in metabolic syndrome.
Inflammation is a common theme connecting all the metabolic syndrome risk
factors (Black, 2003; Ghanim, et al. 2004; Wexler, et al. 2005). It plays a role in elevated
blood pressure, dyslipidemia, impaired glucose tolerance, and obesity (Black, 2003;
Ghanim, et al. 2004; Wexler, et al. 2005). Exercise may reduce these risk factors by
reducing levels of prioinflammatory cytokines and APPs. Reductions in these
inflammatory modulators may, for example, reduce blood pressure by improving insulin
resistance and hyperinsulinemia, by reducing norepinephrine (NE) secretion, and by
enhancing the vasodilatory effects of nitric oxide (NO) (Wexler, et al. 2005).
Exercise may also improve dyslipidemia, via reductions in inflammatory
modulators. Exercise, particularly aerobic exercise, leads to a significant increase in
HDL cholesterol concentrations and a significant decrease in TG concentrations
(Rattigan, 2001; LeMura & von Duvillard, 2004). HDL elevation ranges from 2 mg/di to
8 mg/di or 4-22%, while TG concentrations are reduced by 5 mg/d1 to 38 mg/di or 437%. It is thought that the metabolic demands of exercise produce changes in lipid
regulatory enzyme activity (LeMura & von Duvillard, 2004). A link between
lipoprotein lipase (LPL) and increased HDL, particularly HDL2, and decreased TG
concentrations following exercise has been firmly established (LeMura & von Duvillard,
2004). LPL activity appears to increase transiently after a single bout of exercise. It
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reaches a peak approximately 24 hours following exercise (Greiwe, JS, Holloszy J,
Semenkovich, 2000; LeMura & von Duvillard, 2004). It may be that exercise enhances
LPL activity via reductions in proinflammatory cytokines. Sympathetically induced
cytokines depress lipoprotein lipase (LPL) (Black, 2003). In mice, TNF-a and IL-6 have
been found to reduce LPL activity (Black, 2003). Hence, exercise may reduce
dyslpidemia, at least in part, via a reduction in inflammation.
Regular exercise has also been found to improve glycemic control. This too may
be due to a reduced inflammatory response. Regular exercise has been found to increase
the expression of GLUT 4 transporters (Greiwe, Holloszy, & Semenkovich, 2000;
Henriksen, 2002; Raftigan, 2001; Zheng, 2001) and the expression of insulin receptor
substrate-1 (IRS-1) (Henriksen, 2002). These alterations may be due in part to a
reduction in TNF-a and IL-6, respectively. Exercise has been found to improve glucose
tolerance (Rattigan, 2001) and both peripheral and hepatic insulin sensitivity (LeMura &
von Duvillard, 2004). Improvements in glucose tolerance and insulin sensitivity will
likely lead to reduced cytokine and APP release, further improving glycemic control.
It may be that exercise reduces the inflammatory response via a reduction in body
mass, particularly a reduction in visceral adiposity (Riechman, et al., 2002; Tracy, 2001).
Numerous researchers have found strong positive associations between hs-CRP and waist
girth, body fat mass, and visceral adiposity (LaMonte et al., 2002; Rawson et al., 2003;
Wannamethee et al., 2002). It is now recognized that adipose tissue functions, in part, as
an immune organ (Wisse, 2004). It secretes many immunomodulatory factors and sends
inflammatory signals known to cause insulin resistance (Wisse, 2004). Ghanim et al.
(2004) found increased intranuclear NF-KB binding and increased concentrations of TNF68

a and IL-6 in obese subjects. This proinflammatory state may contribute to insulin
resistance in obese individuals as well as those with metabolic syndrome. Hence,
exercise may reduce the inflammatory response via a reduction in body mass.
At this time there are no specific guidelines suggesting the amount of physical
activity required to reduce inflammation. We found, through Pearson Chi-square
analysis, that participants engaging in 2-3 hours of exercise per week had hs-CRP levels
< 2.5 mg/L (p = 0.01817), which is considered low to moderate risk. This finding
supports the Surgeon General's physical activity recommendations and recommendations
set by the American College of Sports Medicine (U.S. Department of Health and Human
Services, 1996; Jakicic, 2001).
B. Strengths and Limitations
The present study was based on sound theoretical measurements. Validated
measures of blood pressure, body mass index, body fat percent, cardiorespiratory fitness,
and hs-CRP were used. These tools, which have been used for years, increase the
probability that variables were measured correctly.
When designing the study a medium effect size was assumed. Power analysis
was conducted using the statistical software GPOWER (Faul & Erdfelder, 1992).
Multiple regression analysis was the statistical test used to determine power along with a
medium effect size (0.15), an alpha of 0.05, and power of 0.80. The total sample size
needed according to the GPO WER analysis was 131 participants.
Due to the retrospective nature of this study we had a few limitations. Although
we had a sufficient number of participants (n = 173), some data was lacking. The
variable, percent body fat, required over 100 imputations to fill in missing data, hence,
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we chose not to include it in any analyses. We were, therefore, unable to determine if
exercise reduced hs-CRP independent of body fat percent.
The proposed study had a few other possible limitations: (1) reporting bias, (2)
health habits of regular exercisers, (3) failure to control physical activity prior to blood
draw, and (4) lack of detailed medication history prior to blood draw. Participants may
have embellished when filling out the physical activity portion of the PWP. This
respondent bias could threaten the studies validity. To compensate for this possible bias
we utilized a second measure of cardiorespiratory fitness level, a Bruce Protocol
treadmill test. Treadmill test time is highly correlated with measured maximal oxygen
uptake (Pollock, et al., 1976). Therefore, the present study used an objective laboratory
measurement of cardiorespiratory fitness that reduces the misclassification bias often
seen from physical activity self-reports.
People that exercise regularly may also engage in other positive health behaviors,
thereby reducing hs-CRP levels. Regular exercisers, for example, may have healthier
diets than those that do not exercise regularly (Church 2002). This could influence their
hs-CRP levels. In addition to healthier eating habits, regular exercisers may have
reduced stress, anxiety, and depression (Petruzzello, Landers, Hatfield, Kubitz, and
Salazar, 1991; Plante, Unger, Hutchinson, and Faigenbaum, 1990) compared to nonexercisers. Mental state may influence markers of inflammation (Appels, Bar, Bar,
Bruggeman, and DeBaets, 2000). According to Black (2003), an acute phase reaction
may be induced by stress alone. IL-6 is the central mediator of the acute phase reaction
and it facilitates the production of several acute phase proteins, including hs-CRP.
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Hence, if a person exercises regularly, thereby reducing stress, he or she may in turn
decrease hs-CRP levels independently of exercise.
Intense exercise leads to increased inflammation, hence hs-CRP levels will be
elevated (Mattusch et al. 2000). The participants were not instructed to refrain from
exercising prior to the blood draw. If a participant engaged in some form of exercise
prior to the blood draw hs-CRP levels could have been transiently elevated, thereby
affecting the study's validity.
Research has found certain medication influence hs-CRP values. Medications
such as statins, fibrates, and niacin appear to reduce hs-CRP, while hormone replacement
therapy appears to elevate hs-CRP levels (Pearson et al., 2003). The PWP does not
provide detailed medication history and lack of this knowledge could have affected
validity.
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CHAPTER 6
CONCLUSIONS AND RECOMMENDATIONS

A. Conclusions
There is increasing evidence that atherosclerosis is a dynamic and progressive
disease resulting from the combination of inflammation and endothelial dysfunction.
Advances in basic and experimental science have established that inflammation is
involved in mediating all stages of this disease from initiation through progression and,
ultimately, to atherosclerotic plaque complications (Pearson et al., 2003; Libby, Ridker,
& Maseri, 2002). These new findings not only provide a link between risk factors and
the mechanisms of atherogenesis, but the connection between inflammation and
atherosclerosis also provides predictive and prognostic information (Libby, Ridker, &
Maseri, 2002). Several markers of the inflammatory cascade have been examined as
potential tools in the prediction of cardiovascular events. Hs-CRP is one of those
markers and has generated much interest (Szmitko et al., 2003). Emerging evidence
suggests that hs-CRP is one of the strongest independent predictors of cardiovascular
events and may play a functional role in the atherosclerotic disease process (Szmitko et
al., 2003; Yeh & Willerson, 2003). Hs-CRP appears to be even better than low-density
lipoprotein (LDL) cholesterol at predicting cardiovascular events. This new information
is profound and is beginning to change the way we screen and manage patients (Yeh &
Willerson, 2003).
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In addition to hs-CRP's ability to predict cardiovascular events, it also appears to
add prognostic value to all levels of the metabolic syndrome (Szmitko et al., 2003;
Ridker, 2003; Festa, D'Agostino, Howard, Mykkanen, Tracy, and Haffner, 2000). In the
Insulin Resistance Atherosclerosis Study (IRAS), Festa et al. (2000) found that hs-CRP
levels in non-diabetic subjects increased in a monotonic fashion as the number of
metabolic disorders increased. According to Ridker (2003), insulin sensitivity and
impaired fibrinolysis, which are additional factors associated with the metabolic
syndrome, also appear to be associated with hs-CRP. Hs-CRP also appears to predict
type 2 diabetes (Ridker, 2003). Risk for developing type 2 diabetes appears to increase 4
to 6-fold in individuals with hs-CRP levels >3mg/L. These studies support the
interconnection between atherosclerosis, metabolic disorders, and inflammation.
Although the mechanisms are unclear, evidence suggests that physical activity
modifies the inflammatory process. This reduction in inflammation may in turn reduce
risk factors seen in the metabolic syndrome. At this time only a few studies have
examined the effects of exercise, hs-CRP, and the metabolic syndrome. Hence, the
purpose of this study was to confirm and extend existing data regarding the relationship
between hs-CRP, the metabolic syndrome, and cardiorespiratory fitness (CRF). The
following is a list of study conclusions:
(1) Hs-CRP increases linearly with the number of metabolic syndrome
characteristics.
(2) Hs-CRP is inversely associated with CRF level.
(3) CRF level is inversely associated with the number of metabolic syndrome
characteristics.
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(4) A positive relationship was seen between CRF level and exercise pattern as
measured by self report.
(5) Participants engaging in 2-3 hours of physical activity per week had hs-CRP
levels < 2.5 mg/L placing them in low to moderate risk categories.
B. Research Recommendations
More research is clearly needed to assess the relationship between hs-CRP,
physical activity, metabolic syndrome, and atherosclerosis. A number of questions
still remain.
(1) Does the type of physical activity affect hs-CRP level? For example, do
anaerobic activities such as weight lifting or soccer reduce hs-CRP to the same
extent as activities that primarily stress the aerobic energy system.
(2) Does ones enjoyment of the physical activity affect the inflammatory response?
Psychological states have been associated with increased biomarkers of
inflammation (Appels, Bar, Bar, Bruggeman, and DeBaets, 2000). Hence, if an
individual perceives the type of physical activity as unpleasant the inflammatory
response may be activated rather than reduced.
(3) Although the present study and others have demonstrated an inverse relationship
between inflammatory markers, such as hs-CRP, and physical activity,
mechanisms remain unclear. Several theories exist, however, more research is
required to determine possible mechanisms.
(4) It is unclear whether exercise reduces risk factors seen in the metabolic syndrome,
thereby reducing inflammation or whether exercise reduces inflammation, thereby
reducing the metabolic syndrome risk factors. More research is required to
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address the inflammatory response with regard to exercise, hs-CRP, and the
metabolic syndrome criteria.
(5) Is the association seen between physical activity and lowered hs-CRP mediated
by reduced body fat? At this time study results are conflicting regarding the role
body fat plays in this relationship. It was our intent to examine this controversial
question, however, we did not have an adequate number of participants with
percent body fat measured to answer it confidently.
C. Practice Recommendations
Current research is beginning to support the theory that hs-CRP is more than just
a biomarker for CVD. Hence, therapies directed at its reduction appear to be valuable.
Therapies, such as aspirin or statin-class medications, have been shown to reduce hsCRP. Obisesan et al. (2004) stated that statin therapy has been shown to decrease hsCRP by 13-17%. Controversy, however, exists as to whether statin therapy is appropriate
in primary prevention in individuals with high hs-CRP, but normal lipid levels.
Therefore, lifestyle therapy may be more appropriate in these individuals.
Physical activity may even reduce hs-CRP to a greater extent than some
pharmacological therapies. Mattusch et al. (2000) found that nine months of endurance
training reduced hs-CRP levels by 31% when compared to non-training controls and
Smith, Dykes, Douglas, Krishnaswamy, and Berk (1999) observed a 35% reduction in hsCRP in individuals (n = 43) at high risk of ischemic heart disease following six months of
supervised exercise training.
Our findings strengthen the argument that regular physical activity is a valuable
form of lifestyle therapy. Regular exercise and improved cardiorespiratory fitness level
75

are important means of reducing risk factors associated with atherosclerosis, diabetes,
and the metabolic syndrome. Our findings support the ATP-III report, which stresses the
importance of using exercise as first-line therapy for the management of the metabolic
syndrome (Festa et al., 2000, Tracey, 1997).
Identifying individuals with elevated hs-CRP and the metabolic syndrome is
imperative. Once a patient has been identified as having the metabolic syndrome and/or
elevated hs-CRP, the Preventive Care Specialist should prescribe exercise therapy via
health education classes and/or individual counseling. Unfortunately, guidelines have not
been established for the reduction of hs-CRP.
The present study found that participants engaging in 2-3 hours of exercise per
week had hs-CRP levels <2.5 mg/L, which is considered low to moderate risk. This
finding supports the Surgeon General's physical activity recommendations and
recommendations set by the American College of Sports Medicine (ACSM). The
Surgeon General's report on physical activity advices people of all ages engage in a
minimum of 30 minutes of moderate physical activity, such as brisk walking, on most, if
not all, days of the week to improve health and reduce risk of chronic disease (U.S.
Department of Health and Human Services, 1996). The ACSM recommends individuals
attain a minimum of 150 minutes per week of moderate-intensity exercise for health
benefits (Jakicic, 2001). This moderate amount of physical activity may be ideal for
reducing inflammation and its associated risk factors. Participating in moderate amounts
of physical activity along with additional lifestyle therapies, such as stress reduction and
proper nutrition, will likely reduce inflammation, the metabolic syndrome, and the
number one killer in the U.S., cardiovascular disease.
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